XRP has entered a pivotal phase as institutional adoption increases and regulatory clarity reshapes its market prospects.
The resolution of Ripple’s case with the U.S. Securities and Exchange Commission (SEC) in March 2025 cleared a long-standing obstacle, confirming that XRP is not a security in secondary transactions. This milestone has motivated major institutions to get involved.
XRP ETF Launch and Institutional Catalysts Drive Rally
The debut of the REX-Osprey XRP ETF (XRPR) marked a notable regulatory shift, with $37.7 million in first-day trading volume.
BlackRock’s partnership with Ripple on its RLUSD stablecoin and Ripple’s application for Federal Reserve payment access through a national trust bank charter showcase the project’s growing institutional presence.
Ripple’s On-Demand Liquidity network, which processed $1.3 trillion in Q2 2025, further strengthens XRP’s role in cross-border settlements.
September’s rally saw XRP rise by 385%, stabilizing between $2.86 and $2.87 while whales accumulated tens of millions of tokens.
With six more ETF applications pending approval in October and CME preparing to list XRP options on October 13, the token’s bullish catalysts remain strong.
Analysts project medium- to long-term price targets ranging from $5 to $22, with some anticipating $30 or higher by 2026.
XRP's price trends sideways on the daily chart. Source: XRPUSD on Tradingview
Technical Outlook: Key Levels to Watch
XRP remains above its $2.80 support level, even as volatility continues. Resistance is forming around $3.00, with a breakout likely to pave the way toward $3.40, $4.00, and ultimately $5. Surpassing the $5 mark could boost momentum toward $7.
On the downside, immediate support is at $2.60, with further levels at $2.25 and $2.00. Technical indicators are still favorable, with the CCI (50) and Directional Movement Index indicating bullish signs. Traders are considering dip-buying around $2.60, with stop losses near $2.00 and profit targets between $4 and $5.
Whale Influence and ETF Scrutiny
Despite rising institutional confidence, concerns over concentrated XRP ownership persist. The recent Cyber Hornet ETF filing with the SEC flagged whale dominance as a potential risk, arguing that large holders retain the power to influence price movements disproportionately.
Unlike Bitcoin or Ethereum, XRP’s pre-minted supply structure increases liquidity concerns, making it more vulnerable to large transactions. Regulators worldwide have taken notice, with high-value transfers now under closer scrutiny.
Nonetheless, the growing number of institutional products and consistent retail participation suggest that XRP is poised to maintain its momentum, even as debates around whale activity persist.
Cover image from ChatGPT, XRPUSD chart from TradingView
2025-09-29 22:132mo ago
2025-09-29 18:012mo ago
Bitcoin Whale Awakens After 12 Years to Move $44 Million in BTC
In brief
An old address holding 400 Bitcoin worth over $44 million has moved their "digital gold."
The coins had sat in the digital wallet since November 2013. Bitcoin is up 16,000% since then.
A growing number of "Satoshi-era" investors have moved their Bitcoin in recent months with BTC steadily above $100K.
Another long-term Bitcoin investor is back in action and making moves.
Data from Arkham Intelligence shows that an address holding over $44 million in digital coins made a transaction after 12 years of dormancy.
Sunday was the first time the 400 Bitcoin had been touched since they arrived in the digital wallet in November 2013— just four years after the oldest blockchain came to life.
Back then, the price of Bitcoin stood at around $720, according to CoinGecko. It's now trading for over $114,000—a nearly 16,000% rise. As is often the case, it's unclear who owns the wallet, as such personally identifying information isn't included on the blockchain.
Back in 2013, the lowest price the oldest cryptocurrency touched was a mere $13. It soared to over $1,132 by the end of the year.
Old addresses holding such large amounts of Bitcoin likely belong to miners—people or companies—who started minting new coins during the digital asset's early years.
Back then, new coins could be produced using desktop computers. But now in the increasingly industrialized Bitcoin mining world, companies use warehouses full of computers to process transactions on the crypto network.
A number of big, long-term Bitcoin holders—known as "whales"—have started moving coins this year as the cryptocurrency dubbed "digital gold" trades comfortably above $100,000. Such moves have, in the past, spooked markets, as traders largely interpret such reactivations of old wallets as an intention to sell off the stash.
At the moment, market sentiment on Bitcoin has once again flipped bullish, with users on Myriad—a prediction market developed by Decrypt's parent company Dastan—now favoring a move to $125K over a drop to $105K at nearly 58%. Those odds had dropped as low as 29% just yesterday.
Back in July, a whale sold more than 80,000 Bitcoin—over $9 billion at the time—after holding the coins for 14 years. Analysts were initially puzzled, but institutional crypto firm Galaxy later revealed it had executed the sale for the unidentified Satoshi-era investor.
Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.
2025-09-29 22:132mo ago
2025-09-29 18:012mo ago
Dormant Bitcoin Giant Reemerges, Moves $45 Million After Over a Decade
In an unexpected turn of events within the cryptocurrency market, a long-inactive Bitcoin wallet has suddenly become active again, moving a substantial 400 BTC, equivalent to approximately $45.6 million. This significant transaction occurred at block height 916840, marking the wallet's first activity in nearly 12 years.
2025-09-29 22:132mo ago
2025-09-29 18:062mo ago
Ethereum Price Prediction: Surprise Bounce Recovers $4,000 – On-Chain Signals Point to Greater Gains
Following approval of generic listing standards, SEC has instructed the Withdrawal of pending 19b-4s so ETF issuers proceed via S-1s. The shift has reduced review time, has coincided with GDLC's approval, and has kept October–November deadlines in play for Solana, XRP, and others.
2025-09-29 21:122mo ago
2025-09-29 16:512mo ago
AI market bubble concerns grow, plus the government shutdown & what's powering gold to new highs
Market Domination anchor Josh Lipton breaks down the latest market news for September 29, 2025. Epistrophy Capital Research chief market strategist Cory Johnson joins Market Domination host Josh Lipton for a conversation about the risks of the AI market bubble and its similarities to the Dot-Com crash.
Sept 29 (Reuters) - Automated digital wealth management firm Wealthfront Corporation on Monday filed for an initial public offering in the United States.
In recent months, the U.S. IPO market has kicked back into action from the earlier slowdown triggered by trade policy uncertainty, with new offerings receiving considerable investor attention.
Sign up here.
Wealthfront will list on the Nasdaq Stock Market under the "WLTH" symbol. Goldman Sachs, J.P. Morgan and Citigroup are among the underwriters for the offering.
Wealthfront, founded in 2008 by Andy Rachleff and Dan Carroll, provides automated tools such as cash accounts, ETF and bond investing, as well as trading and low-cost loans to its clients.
The company, a pioneer in using automation to build low-cost investment portfolios, has incorporated elements of artificial intelligence into its financial planning software.
Reporting by Prakhar Srivastava in Bengaluru; Editing by Alan Barona
Our Standards: The Thomson Reuters Trust Principles., opens new tab
2025-09-29 21:122mo ago
2025-09-29 16:542mo ago
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025
2025-09-29 21:122mo ago
2025-09-29 16:542mo ago
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 17, 2025.
So what: If you purchased Cytokinetics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Cytokinetics class action, go to https://rosenlegal.com/submit-form/?case_id=45298 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that Cytokinetics expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 Prescription Drug User Fee Act ("PDUFA") date, and failed to disclose material risks related to Cytokinetics' failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Cytokinetics class action, go to https://rosenlegal.com/submit-form/?case_id=45298 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
2025-09-29 21:122mo ago
2025-09-29 16:572mo ago
NYSE American to Commence Delisting Proceedings Against dMY Squared Technology Group, Inc. (DMYY)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below (“Securities”) of dMY Squared Technology Group, Inc. (the “Company”) from NYSE American. Trading in the Company’s Securities will be suspended immediately.
NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination within (i) 36 months of the effectiveness of its initial public offering registration statement, or (ii) such shorter period that the Company specified in its registration statement.
The Company has a right to a review of NYSE Regulation staff’s determination to delist the Company’s Securities by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company’s Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
More News From NYSE Regulation
Back to Newsroom
2025-09-29 21:122mo ago
2025-09-29 16:592mo ago
Bit Digital to raise $100M in proposed convertible notes offering
Bit Digital Inc (NASDAQ:BTBT) announced a proposed registered underwritten public offering by the company of $100 million total principal amount of its convertible senior unsecured notes due 2030, subject to market and other conditions.
The digital asset platform said net proceeds from the offering will be used primarily to purchase Ethereum and may be used by the company for general corporate purposes, including potential investments, acquisitions and other business opportunities relating to digital assets.
The interest rate, initial conversion rate and certain other terms of the notes will be determined at the time of pricing.
Bit Digital stated that the notes will mature on October 1, 2030, unless earlier converted, redeemed or repurchased.
The company added that it intends to grant the underwriters in the offering a 30-day option to purchase up to an additional $15 million total principal amount of notes on the same terms and conditions, solely to cover over-allotments.
Barclays, Cantor and B Riley Securities are acting as joint lead book-running managers for the offering.
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Femto Technologies Announces Changes to its Board of Directors
(September 29, 2025) – TheNewswire - Femto Technologies Inc. (OTCID: FMTOF) (“Femto” or the “Company”),
is pleased to announce the appointment of Mor Bzizinsky to its board of directors. Ms. Bzizinsky received a B.A. in Law and Economics from the College of Management in Rishon LeZion, Israel. She has been an attorney since 2012 and owns and manages a private law practice.
Ms. Bzizinsky is also nominated to the Audit Committee of the company.
Mr. Yftah Ben Yaackov states: “We are very pleased to have Miss. Bzizinsky join the board as an
independent director. Ms. Bzizinsky’s business and legal background as well as the fact that she is a woman will help us advance our entry into the Femtech market with our innovative products”
About Femto Technologies Inc.
Femto Technologies Inc. (OTCID: FMTOF) is a cutting-edge femtech company spearheading transformative advancements in wellness technology. With a strong emphasis on AI-driven solutions, Femto is dedicated to innovating products that enhance well-being through intelligent technology integration.
ABOUT SENSERA
Sensera is a feminine wellness device designed to bridge the gap between feminine pleasure and wellness, providing a holistic self-care experience that adapts to a woman’s changing needs. Sensera utilizes Femto’s proprietary Smart Release System (SRS) technology, including machine learning and AI, to enhance feminine wellness. Sensera is a CES Innovation Awards® 2025 Honorary in the AI category.
For more information on Sensera, please visit www.senserawellness.com and follow us on Instagram, Facebook, and YouTube.
This press release includes certain statements that may be deemed “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended and under Canadian securities laws. When used in this press release, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward‐looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements.
Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including future financial performance, unanticipated regulatory requests and delays, final patents approval, and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company's management's discussion and analysis for the year ended December 31, 2024 and annual information form dated March 31, 2025, which are available under the company's profile at www.sedarplus.ca, and in the Company’s Annual Report on Form 20-F for the year then ended that was filed with the U.S. Securities and Exchange Commission on March 31, 2025. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward‐looking statements, except as required by law. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forward‐looking statements.
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Rogers Communications 3Q25 Investment Community Teleconference October 23, 2025 at 8:00 a.m. ET
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) plans to release its third quarter 2025 financial results on Thursday, October 23, 2025, before North American financial markets open. The results will be distributed by newswire and posted at investors.rogers.com. Rogers management will host its quarterly teleconference with the investment community to discuss the results and outlook at 8:00 a.m. ET.
A live webcast of the teleconference will be available on the Investor Relations section of Rogers website at investors.rogers.com. Alternatively, the teleconference can be accessed by dialing 416-639-5883 (1-844-282-4459 toll free Canada/USA). When prompted, callers are required to enter passcode 3793238# for admittance to the call.
An archive of the presentation will be available at this same website following the teleconference. In addition, a telephonic re-broadcast will be available for two weeks following the teleconference by dialing 1-855-669-9658 (toll free Canada/USA) and providing access code 7368124#.
About Rogers:
Rogers is Canada’s leading communications and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or investors.rogers.com.
For further Information:
Investor Relations
1-844-801-4792 [email protected]
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Viomi Celebrates 7th Nasdaq Anniversary with New Brand Campaign and U.S. Launch of AI Alkaline Mineral Water Purifier, MASTER M1
GUANGZHOU, China, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd. (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading innovator of home water solutions in China, today celebrated the 7th anniversary of its Nasdaq listing by announcing two major strategic initiatives. Viomi unveiled a brand elevation campaign featuring a renowned celebrity spokesperson and an Olympic champion. Concurrently, the Company is strengthening its U.S. market presence with the U.S. debut of its first AI alkaline mineral water purifier, MASTER M1, now available on Amazon. Leveraging AI technology to replicate pure mineralization, the device delivers clean, mineral-rich water to households across the United States.
Brand Strategy Elevated with New Celebrity Partnerships in China
In China, Viomi has named renowned Chinese actress Shengyi Huang as its new national brand spokesperson. Known for her elegant and healthy image, Ms. Huang will embody Viomi’s “AI for Better water” brand philosophy, promoting healthier hydration habits and connecting with a new generation of consumers.
Furthering its brand-building efforts, Viomi also welcomed Olympic diving champion Liang Tian as a brand partner. Mr. Tian, accompanied by Guoxiang Li, General Manager of JD.com Home Appliances, toured Viomi’s RMB 1 billion Water Purifier Gigafactory – one of the most advanced facilities of its kind in the world. Impressed by the facility’s cutting-edge automation, intelligent production processes, and full traceability system, Mr. Tian commended Viomi’s deep commitment to technology and quality.
During his visit, Mr. Tian sampled tea brewed with water from Viomi’s Kunlun 4 Pro AI alkaline mineral water purifier, noting its superior clarity and aroma. The experience highlighted how the mild alkaline, mineralized water enhances the taste of beverages, reinforcing consumer confidence in Viomi’s innovation capability and product excellence.
MASTER M1 Launches on Amazon U.S. for US$899
Marking a key milestone in its global strategy, Viomi has officially launched the MASTER M1 AI alkaline mineral water purifier on Amazon U.S. This move brings a premium, AI-powered drinking water solution to American households, making advanced water purification technology more accessible.
Key Features of MASTER Series M1:
Pure, pH+ Alkaline Mineral Water: Replicates natural spring water by enriching it with essential minerals like calcium, magnesium, potassium, sodium, strontium, and metasilicic acid for a balanced taste. It meets the human body’s demand for multiple minerals and is closer to pure mineral water.Precision 9-Stage RO Filtration: Removes 99% of harmful contaminants down to 0.0001 micron, ensuring exceptionally clean and safe water.AI-Powered Smart Faucet: A touch-screen display provides real-time data on water quality (TDS), water volume, and filter status for a seamless, intelligent experience.Cost-Effective, Low-Maintenance Design: The long-life filter lasts up to 4 years and is designed for simple, tool-free DIY replacement, reducing cost and maintenance hassle. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented, “The launch of the MASTER M1 on Amazon U.S. demonstrates our commitment to ‘AI for Better water.’ With our ongoing R&D breakthroughs, we are advancing our ‘Global Water’ strategy and brand empowerment, raising awareness of healthy drinking water worldwide. Following strong revenue and operating profit growth in the first half of this year, we will continue to lead innovation in water purification, deliver impactful new products, and maintain our leadership in the global healthy drinking water market.”
About Viomi Technology
Viomi’s mission is “AI for Better Water,” utilizing AI technology to provide better drinking water solutions for households worldwide.
As an industry-leading technology company in home water solutions, Viomi has developed a distinctive “Equipment + Consumables” business model. By leveraging its expertise in AI technology, intelligent hardware and software development, the Company simplifies filter replacement and enhances water quality monitoring, thereby increasing the filter replacement rate. Its continuous technological innovations extend filter lifespan and lower user costs, promoting the adoption of water purifiers and supporting a healthy lifestyle while effectively addressing the rising global demand for cleaner, fresher and healthier drinking water. The Company operates a world-leading “Water Purifier Gigafactory” with an integrated industrial chain that boasts optimal efficiency and facilitates continuous breakthroughs in water purification. This state-of-the-art facility enables Viomi to achieve economies of scale and accelerate the global popularization of residential water filtration.
For more information, please visit: https://ir.viomi.com.
For investor and media inquiries, please contact:
In China:
Viomi Technology Co., Ltd
Claire Ji
E-mail: [email protected]
In the United States:
Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
E-mail: [email protected]
Photos accompanying this announcement are available at
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) (“Eloro”, or the “Company”) is pleased to announce that in connection with the annual and special meeting of the Company`s shareholders (the “Meeting”), that was held virtually on September 29, 2025, and in accordance with TSX reporting requirements, the following voting results were obtained.
A total of 42,194,396 common shares, which equates to 44.56% of the Company`s issued and outstanding common shares, were represented the Meeting. Shareholders voted in favour of the election of the seven director nominees as follows:
NOMINEE
VOTES
FOR%
FOR VOTES
WITHHELD %
WITHHELDThomas Larsen36,494,21199.660124,5200.340Francis Sauve36,375,27499.335243,4570.665Alexander Horvath36,392,57499.382226,1570.618Dusan Berka36,143,38198.702475,3501.298Richard Stone36,149,42798.718469,3041.282Pablo Ordoñez36,150,03498.720468,6971.280Caroline Cathcart36,374,15099.332244,5810.668 Shareholders also voted in favour of the other items of business considered at the Meeting, being the setting of the number of directors of the Company at seven, with the directors authorized to determine the number of directors of the Company by resolution of the directors, the re-appointment of RSM Canada LLP as the Company’s auditors, and the approval of all unallocated awards, rights or other entitlement under the Corporation’s Long-Term Incentive Plan, as required by the rules of the Toronto Stock Exchange. Pursuant to Section 11.3 of National Instrument 51-102, the Company filed a “Report of Voting Results” on September 29, 2025, under the Company’s filings on SEDAR+ (www.sedarplus.ca).
About Eloro Resources Ltd.
Eloro is an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska project, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department, in southern Bolivia. A NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR+. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru some 50 km south of the Lagunas Norte Gold Mine and the La Arena Gold Mine.
For further information please contact either Thomas G. Larsen, Chairman and CEO or Jorge Estepa, Vice-President at (416) 868-9168.
Information in this news release may contain forward-looking information. Statements containing forward-looking information express, as at the date of this news release, the Company’s plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and are believed to be reasonable based on information currently available to the Company. There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
ZK International Group Co., Ltd. Announces Earnings Results for the First Half of Fiscal Year 2025
, /PRNewswire/ -- ZK International Group Co., Ltd. (ZKIN) ("ZK International" or the "Company"), a designer, engineer, manufacturer, and supplier of patented high-performance stainless steel and carbon steel pipe products primarily used for water and gas supplies, today announced its unaudited financial results for the six months ended March 31, 2025.
Financial Highlights for the First Half of Fiscal Year 202 5
For the Six Months Ended March 31,
($ millions, except per share data)
2025
2024
% Change
Revenue
$
40.00
$
52.89
(24.37)
%
Gross profit
$
2.19
$
3.35
(34.63)
%
Gross margin
5.47
%
6.33
%
-0.86
%
pp*
Income loss from operations
$
(0.49)
$
(0.16)
197.83
%
Operating margin
(1.22)
%
(0.31)
%
-0.91
%
pp*
Net loss
$
(0.80)
$
(0.48)
66.48 %
Diluted earnings per share
$
(0.02)
$
(0.01)
-
* pp: percentage point(s)
Revenue decreased by 24.37% to $40.00 million for the six months ended March 31, 2025 from $52.89 million for the six months ended March 31, 2024. During the first fiscal half of 2025, we faced a decrease in demand for our piping products, mainly due to the slow recovery in the real estate market (such as reduced construction projects and weakened investment momentum) during the fiscal half period. Despite our efforts to manage costs related to raw materials (including nickel, a key component of stainless steel), the dampened market demand not only lowered our sales volume but also limited our ability to adjust pricing. As a result, the combined effect of weaker sales and challenging market conditions led to the revenue decline for the six months ended March 31, 2025.
Gross profit decreased by 34.63% to $2.19 million. Gross margin was 5.47%, compared to 6.33% for the same period of the prior fiscal period. The falling revenue, along with increased raw materials costs (particularly for stainless steel which is a key component of our products), has outpaced our cost optimization efforts which led to a decline in gross margin.
Loss from operations was $0.49 million, compared to loss from operations of $0.16 million for the same period of the prior fiscal year. Operating margin was (1.22)%, compared to (0.31)% for the same period of the prior fiscal year.
Net loss was $0.8 million. This compared to a net loss of $0.48 million for the same period of the prior fiscal year.
Financial Results for the First Half of Fiscal Year 202 5
Revenue
Revenue decreased by $12,890,784.00 or 24.37%, to $39,996,372 for the six months ended March 31, 2025 from $52,887,156 for the six months ended March 31, 2024. During the first fiscal half of 2025, we faced a decrease in demand for our piping products, mainly due to the slow recovery in the real estate market (such as reduced construction projects and weakened investment momentum) during the fiscal half period. Despite our efforts to manage costs related to raw materials (including nickel, a key component of stainless steel), the dampened market demand not only lowered our sales volume but also limited our ability to adjust pricing. As a result, the combined effect of weaker sales and challenging market conditions led to the revenue decline for the six months ended March 31, 2025.
Gross Profit
Our gross profit decreased by $1,163,908, or 34.74%, to $2,186,102 for the six months ended March 31, 2025 from $3,350,010 for the six months ended March 31, 2024. Gross profit margin was 5.47% for the six months ended March 31, 2025, as compared to 6.33% for the six months ended March 31, 2024. The decrease of our gross profit was mainly attributable to the revenue decline amid real estate market sector. Moreover, persistent raw materials costs (particularly for stainless steel, a key component of our products) have outpaced our cost optimization efforts, which led to a decline in gross margin.
Selling and Marketing Expenses
We incurred $881,686 in selling and marketing expenses for the six months ended March 31, 2025, compared to $880,824 for the six months ended March 31, 2024. Selling and marketing expenses increased by $862, or 0.10%, during the six months ended March 31, 2025 compared to the six months ended March 31, 2024.
General and Administrative expenses
We incurred $1,396,466 in general and administrative expenses for the six months ended March 31, 2025, compared to $2,010,566 for the six months ended March 31, 2024. General and administrative expenses decreased by $614,100 or 30.54%, for the six months ended March 31, 2025 compared to the same period in 2024. The decrease is primarily due to reductions in consulting expenses and employee related costs.
Research and Development Expenses
We incurred $396,934 in research and development expenses for the six months ended March 31, 2025, compared to $622,805 for the six months ended March 31, 2024. R&D expenses decreased by $225,871, or 36.27%, for the six months ended March 31, 2025 compared to the same period in 2024.
Income (loss) from Operations
As a result of the factors described above, we incurred operating loss of $488,984 for the six months ended March 31, 2025, compared to operating loss of $164,185 for the six months ended March 31, 2024, an increase of operating loss of $324,799.
Other Income (Expenses)
Our interest income and expenses were $4,052 and $349,499, respectively, for the six months ended March 31, 2025, compared to interest income and expenses of $7,868 and $411,045, respectively, for the six months ended March 31, 2024.
Net Income (loss)
As a result of the factors described above, we incurred net loss of $802,028 for the six months ended March 31, 2025, compared to net loss of $481,753 for the six months ended March 31, 2024, an increase in net loss of $320,275.
Financial Condition
As of March 31, 2025, cash and cash equivalents, restricted cash and short-term investments totaled $1.61 million, compared to $4.16 million as of September 30, 2024. Short-term bank borrowings were $11.19 million as of March 31, 2025, compared to $10.26 million as of September 30, 2024.
Accounts receivable was $19.82 million as of March 31, 2025, compared to $22.39 million as of September 30, 2024. Inventories were $15.49 million as of March 31, 2025, compared to $13.53 million as of September 30, 2024. Accounts payable was $2.43 million as of March 31, 2025, compared to $3.13 million as of September 30, 2024.
Total current assets and current liabilities were $55.30 million and $45.39 million, respectively, leading to a current ratio of 1.22 as of March 31, 2025. This compared to total current assets and current liabilities were $62.74 million and $24.89 million, respectively, and current ratio of 1.26 as of September 30, 2024.
About ZK International Group Co., Ltd.
ZK International Group Co., Ltd. is a China-based designer, engineer, manufacturer, and supplier of patented high-performance stainless steel and carbon steel pipe products that require sophisticated water or gas pipeline systems. The Company owns 33 patents, 21 trademarks, 2 Technical Achievement Awards, and 10 National and Industry Standard Awards. ZK International is Quality Management System Certified (ISO9001), Environmental Management System Certified (ISO1401), and a National Industrial Stainless Steel Production Licensee that is focused on supplying steel piping for the multi-billion dollar industries of Gas and Water sectors. ZK has supplied stainless steel pipelines for over 2,000 projects, including the Beijing National Airport, the "Water Cube", and "Bird's Nest", which were venues for the 2008 Beijing Olympics. Emphasizing superior properties and durability of its steel piping, ZK International is providing a solution for the delivery of high quality, highly sustainable, environmentally sound drinkable water not only to the China market but also to international markets such as Europe, East Asia, and Southeast Asia.
For more information please visit www.ZKInternationalGroup.com. Additionally, please follow the Company on Twitter, Facebook, YouTube, and Weibo. For further information on the Company's SEC filings please visit www.sec.gov.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are not guarantee of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict and many of which are beyond the control of ZK International. Actual results may differ from those projected in the forward-looking statements due to risks and uncertainties, as well as other risk factors that are included in the Company's filings with the U.S. Securities and Exchange Commission. Although ZK International believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by ZK International or any other person that their objectives or plans will be achieved. ZK International does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
ZK International Group Co., Ltd. and Subsidiaries
Consolidated Statements of Income and Comprehensive Income (Loss)
For the Six Months Ended March 31, 2025 and 2024 (Unaudited)
(IN U.S. DOLLARS, EXCEPT SHARE DATA)
For the Six Months Ended
March 31,
2025
2024
Revenues
39,996,372
$
52,887,156
Cost of sales
37,810,270
49,537,146
Gross profit
2,186,102
3,350,010
Operating expenses:
Selling and marketing expenses
881,686
880,824
General and administrative expenses
1,396,466
2,010,566
Research and development costs
396,934
622,805
Total operating expenses
2,675,086
3,514,195
Operating income (loss)
(488,984)
(164,185)
Other income (expenses):
Interest expenses
(349,499)
(411,045)
Interest income
4,052
7,868
Other income (expenses), net
46,574
92,816
Total other income (expenses), net
(298,873)
(310,361)
Income (Loss) before income taxes
(787,857)
(474,546)
Income tax provision
(14,171)
(7,207)
Net income (loss)
(802,028)
(481,753)
Net income (loss) attributable to non-controlling interests
(5,227)
-
Net income (loss) attributable to ZK International Group Co., Ltd.
(796,801)
(481,753)
Net income (loss)
(802,028)
(481,753)
Other comprehensive income:
Foreign currency translation adjustment
Total comprehensive income (loss)
(802,028)
(481,753)
Comprehensive income (loss) attributable to non-controlling interests
(1,688)
(9,284)
Comprehensive income attributable to ZK International Group Co., Ltd.
(803,716)
(472,468)
Basic and diluted earnings per share
Basic
(0.15)
(0.11)
Diluted
(0.15)
(0.11)
Weighted average number of shares outstanding
Basic
5,232,469
4,492,280
Diluted
5,232,469
4,492,280
ZK International Group Co., Ltd. and Subsidiaries
Consolidated Balance Sheets
As of March 31, 2025 and September 30, 2024 (Unaudited)
( IN U.S. DOLLARS)
As of September 30,
2024
2023
Assets
Current assets
Cash and cash equivalents
$
1,559,434
$
4,009,387
Restricted cash
46,714
103,917
Short-term Investment
-
50,111
Accounts receivable, net of allowance for doubtful accounts and provision for expected credit loss
of $7,330,890 and $7,580,664, respectively
19,816,792
22,393,810
Notes receivable
750,672
355,761
Prepayment, deposit and other receivable - current
8,166,269
4,657,014
Inventories
15,487,586
13,528,170
Advance to suppliers
9,469,805
17,641,946
Total current assets
55,297,272
62,740,116
Property, plant and equipment, net
7,957,533
8,104,335
Right-of-use asset – Operating lease
212,915
162,103
Intangible assets, net
1,234,704
1,282,939
Deferred tax assets
—
Prepayment, deposit and other receivable - Non-current
261,576
271,201
Long-term prepayment
—
Long-term accounts receivable
4,788,657
5,379,311
Long-term investment
2,037,086
2,046,868
TOTAL ASSETS
$
71,789,743
$
79,986,873
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
2,426,968
$
3,125,104
Accrued expenses and other current liabilities
3,749,209
4,261,080
Operating lease liability - current
-
12,280
Accrued payroll and welfare
2,662,269
2,323,244
Advance from customers
10,081,298
14,861,280
Due to related parties
70,500
216,906
Convertible debentures
4,917,683
4,917,683
Bank borrowings - current
11,194,069
10,259,918
Long-term Bank borrowings - current
9,795,775
9,765,447
Notes payables
493,219
124,957
Total current liabilities
45,390,990
49,867,899
Operating lease liability – non-current
—
Bank borrowings – non-current
-
1,802,468
TOTAL LIABILITIES
$
45,390,990
$
51,670,367
COMMITMENTS AND CONTINGENCIES
—
Equity
Common stock, no par value, 50,000,000 shares authorized, 5,232,469 and 5,163,946 shares
issued and outstanding, respectively
—
Additional paid-in capital
77,886,898
77,886,898
Statutory surplus reserve
3,176,556
3,176,556
Subscription receivable
(125,000)
(125,000)
Retained earnings (Deficits)
(51,245,374)
(50,448,573)
Accumulated other comprehensive loss
(3,449,608)
(2,326,968)
Total equity attributable to ZK International Group Co., Ltd.
26,243,472
28,162,913
Equity attributable to non-controlling interests
155,281
153,593
Total equity
26,398,753
28,316,506
TOTAL LIABILITIES AND EQUITY
$
71,789,743
$
79,986,873
SOURCE ZK International Group Co., Ltd.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Benton Closes $1.836 Million in First Tranche of Private Placement Financing
September 29, 2025 5:00 PM EDT | Source: Benton Resources Inc.
Thunder Bay, Ontario--(Newsfile Corp. - September 29, 2025) - Benton Resources Inc. (TSXV: BEX) ("Benton" or the "Company"), further to its September 17, 2025 and September 23, 2025 news releases, is pleased to announce that it has received conditional approval for its $2.4 million private placement financing (the "Financing"). Further, the Company announces that it has closed a first tranche of the financing, issuing 33,372,910 $0.055 units (the "Units"), for aggregate gross proceeds of $1,835,510.
Each Unit consists of one common share of the Company and one common share purchase warrant ("Warrant"), each Warrant entitling the holder to acquire an additional common share of the Company at $0.10 for a period of 5 years from the date of issue. The Company will use the proceeds from the private placement to advance its Newfoundland projects and for general working capital purposes.
The Financing is subject to final TSX Venture Exchange approval, and all securities issued pursuant to the Financing are subject to a four-month hold from the date of issue.
QP
Stephen House (P.Geo.), Vice President of Exploration for Benton Resources Inc., the 'Qualified Person' under National Instrument 43-101, has approved the scientific and technical disclosure in this news release and prepared or supervised its preparation.
About Benton Resources Inc.
Benton Resources is a well-financed mineral exploration company listed on the TSX Venture Exchange under the symbol BEX. Benton has a diversified, highly prospective property portfolio and holds large equity positions in other mining companies that are advancing high-quality assets. Whenever possible, BEX retains net smelter return (NSR) royalties with potential long-term cash flow.
Benton is focused on advancing its high-grade Copper-Gold Great Burnt Project in central Newfoundland, which has a Mineral Resource estimate of 667,000 tonnes @ 3.21% Cu Indicated and 482,000 @ 2.35% Cu Inferred. The Project has an excellent geological setting covering 25km of strike and boasts six known Cu-Au-Ag zones over 15km that are all open for expansion. Further potential for discovery is excellent given the extensive number of untested geophysical targets and Cu-Au soil anomalies. Phase 1 and 2 drill programs returned impressive results including 25.42 m of 5.51% Cu, including 9.78 m of 8.31% Cu, and 1.00 m of 12.70% Cu. Drilling at the South Pond Gold Zone, approximately 7.5 km north of the Great Burnt Copper-Gold Zone, has confirmed a robust gold-mineralized system over 2.5 km with results of 74.20 m of 1.43g/t Au and 43.75 m of 1.62g/t Au and is open for expansion in all directions.
On behalf of the Board of Directors of Benton Resources Inc.,
"Stephen Stares"
Stephen Stares, President
Parties interested in seeking more information about properties available for option can contact Mr. Stares at the number below.
THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
The information contained herein contains "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements relate to information that is based on assumptions of management, forecasts of future results, and estimates of amounts not yet determinable. Any statements that express predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."
Forward-looking statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation: risks related to failure to obtain adequate financing on a timely basis and on acceptable terms; risks related to the outcome of legal proceedings; political and regulatory risks associated with mining and exploration; risks related to the maintenance of stock exchange listings; risks related to environmental regulation and liability; the potential for delays in exploration or development activities or the completion of feasibility studies; the uncertainty of profitability; risks and uncertainties relating to the interpretation of drill results, the geology, grade and continuity of mineral deposits; risks related to the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; results of prefeasibility and feasibility studies, and the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; risks related to gold price and other commodity price fluctuations; and other risks and uncertainties related to the Company's prospects, properties and business detailed elsewhere in the Company's disclosure record. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements. Investors are cautioned against attributing undue certainty to forward-looking statements. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances. Actual events or results could differ materially from the Company's expectations or projections.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268439
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Allied Critical Metals Expands High Grade Footprint at Borralha Tungsten Project
New Step-Out and Infill Results Build Confidence in Resource Growth and Model Robustness
September 29, 2025 5:00 PM EDT | Source: Allied Critical Metals Inc.
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - Allied Critical Metals Inc. (CSE: ACM) (OTCQB: ACMIF) (FSE: 0VJ0) ("Allied" or the "Company"), which is focused on its 100% owned past producing Borralha and Vila Verde tungsten projects in northern Portugal, is pleased to report assay results from two additional Reverse Circulation (RC) drill holes - Bo_RC_21 and Bo_RC_26 - from its ongoing 5,000-metre campaign at the 100%-owned Borralha Tungsten Project in northern Portugal.
These latest results continue to demonstrate the scale and continuity of mineralization at the Santa Helena Breccia (SHB), with intercepts that support both lateral expansion and model refinement.
Highlights:
Bo_RC_21: This drill hole is a west step-out at the North edge of the St. Helena Breccia that confirms continuity of the recently discovered north-dipping lode outside the current MRE envelope, upgrading this area to a large coherent mineralized "in section" corridor with more than 100 m width.
42.0m at 0.19% WO3 (from 256.0 m to 298.0 m), including:24.0m at 0.28% WO3 (from 256.0 m to 280.0 m)18.0m at 0.34% WO3 (from 256.0 m to 274.0 m)8.0m at 0.40% WO3 (from 266.0 m to 274.0 m)4.0m at 0.62% WO3 (from 266.0 m to 270.0 m)Bo_RC_26: This drill hole is an infill hole targeting the north-central zone, enhancing confidence in the resource model and suggesting western expansion potential.
26.0m at 0.24% WO3 (from 140.0 m to 166.0 m), including:12.0m at 0.38% WO3 (from 140.0 m to 152.0 m)2.0m at 2.02% WO3 (from 140.0 m to 142.0 m)Drill Program Progress
To date, 3,721 metres of RC drilling have been completed out of the planned 5,728 metres, with multiple assay results already confirming thick mineralized zones and consistent grade distribution. The current campaign is designed to support:
The expansion of the Mineral Resource Estimate (MRE), expected in Q4 2025.The development of a robust Preliminary Economic Assessment (PEA).The delineation of potential higher-grade corridors for future mine planning.Roy Bonnell, CEO and Director of ACM, commented: "With each new intercept, we are seeing our understanding of Borralha evolve and strengthen. Bo_RC_21 confirms mineralization well beyond the current model, while Bo_RC_26 tightens the block model in a key zone. Together, these results support both immediate growth and long-term confidence in Borralha's development potential."
New IDFrom (m)To (m)DH length (m) [1]True Width Factor [1]True Width (m) [1]WO3 (%)Bo_RC_14/2552.064.012.0tbd [2]-4.27inc.52.058.06.0"-8.39Bo_RC_15/25164.0166.02.00.881.80.97Bo_RC_17/2552.0152.0100.00.9089.90.21inc.92.0124.032.00.9028.80.33inc.106.0120.014.00.9012.60.52inc.110.0116.06.00.905.40.74Bo_RC_21/25256.0298.042.0tbd [2]unknown0.19inc.256.0280.024.0"unknown0.28inc.256.0274.018.0"unknown0.34inc.266.0274.08.0"unknown0.40inc.266.0270.04.0"unknown0.62Bo_RC_22/25284.0348.064.0tbd [2]unknown0.12inc.316.0332.016.0"unknown0.21Bo_RC_26/25140.0166.026.00.3910.20.24inc.140.0152.012.00.404.70.38inc.140.0142.02.00.400.82.02Notes: [1] Reported intervals are downhole lengths. Estimated true widths were calculated from hole orientation and the interpreted geometry of the mineralized corridors. Estimates may vary locally where geometry changes. Where intervals fall outside the resource block-model domains, true widths are not estimated and only downhole lengths are reported. [2] True widths are unknown, to be defined after further MRE update.
Figure 1 - Drill collar plan showing planned holes for the ongoing 5,728 m RC campaign at the Borralha Project. The red outline delineates the main mineralized breccia zone
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11632/268354_73bff5a8941de85b_001full.jpg
Figure 2 - Geological Cross-Section for hole Bo_RC_21/25.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11632/268354_alliedcritical2.jpg
Strategic Context
These results follow recently reported ultra-high-grade and extensive tungsten intercepts, including 12.0 m @ 4.27% WO₃ (Bo_RC_14/25), and 100.0 m @ 0.21% WO₃ (Bo_RC_17/25), confirming a significant system within the Santa Helena Breccia. Allied is working systematically to define both bulk-mineable zones and higher-grade corridors that can support future underground or hybrid extraction scenarios.
Next Steps
Drilling is ongoing, with further results expected in the coming weeks. Step-out holes are targeting both western and northern extensions of SHB, while infill drilling is refining the core resource model. Results will continue to inform the MRE and subsequent economic studies.
In light of the recent new discovery of the very high grade corridor at the west dip of the central area of the Breccia, the Company has adapted the current campaign towards confirming, and potentially expanding upon the recent very high grade intercepts.
Sampling, QA/QC and Analytical Notes
Drilling was completed using reverse-circulation (RC). All sample bags were pre-labelled with a unique internal sequence number used consistently for the assay sample and corresponding reject. Sampling was conducted on 2.0 m intervals for analytics. For each 2.0 m interval, two 1.0 m reject samples were also collected as representative splits. Splitting was performed at the rig via a rotary splitter integral to the RC cyclone.
Sampling followed pre-prepared sample lists that recorded downhole metreage, sequence, and the placement of Certified Reference Materials (CRMs) and field duplicates. CRMs were inserted at a rate of 1 in 20 samples (5%) and field duplicates at 1 in 20 samples (5%), arranged so that every 10th sample alternated between a CRM and a duplicate.
Analytical and reject samples were boxed at the drill site and transported by company personnel to the project core/logging facility. Analytical samples were stored on labelled pallets pending direct shipment to ALS's preparation laboratory in Seville, Spain. Pulps and rejects were subsequently stored securely in the project logging room.
At ALS Seville, samples were crushed to 70% passing 2 mm, riffle-split to ~250 g, and pulverized using hardened steel to 85% passing 75 μm. Pulps were shipped to ALS Loughrea (Ireland) for analysis. The primary analytical method was ME-MS81 (lithium borate fusion with ICP-MS finish). Base metals were also reported using ME-4ACD81 (four-acid digestion with ICP-MS finish). Over-limit tungsten results were re-assayed using W-XRF15b (lithium borate fusion with XRF). Analytical results were delivered directly by ALS to the Company via secure electronic transfer.
Primary disclosure remains the reported grade and interval length (and true width where known).
To the best of the Company's knowledge, no drilling, sampling, recovery, or other factors have been identified that would materially affect the accuracy or reliability of the data referenced herein.
Qualified Person
The scientific and technical information in this news release has been reviewed and approved by Mr. Vítor Arezes, BSc, MIMMM (QMR) (Membership Nº. 703197, Vice-President Exploration of Allied Critical Metals, who is a Qualified Person for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Mr. Arezes is not independent of Allied Critical Metals Inc. as he is an officer of the Company.
About the Borralha Tungsten Project
Allied's Borralha Tungsten Project is one of the largest and most historically significant past-producing tungsten operations in Western Europe. Located in northern Portugal, Borralha was once the second-largest tungsten mine in the country and supplied strategic materials to European and Allied industries during the 20th century, including both World Wars and the Cold War period.
Today, the project is undergoing a modern revitalization based on a combination of scale, grade, metallurgy, and jurisdictional strength. Mineralization is dominated by coarse-grained wolframite, which is highly desirable in global markets due to its favorable processing characteristics and higher recoveries compared to scheelite-bearing deposits.
Borralha benefits from existing infrastructure, shallow mineralization, and a simple processing route, making it one of the most advanced tungsten development projects in the European Union. These attributes are particularly important in the context of the EU Critical Raw Materials Act (2024/1252) and NATO strategic autonomy initiatives, both of which explicitly identify tungsten as a defense-critical raw material subject to severe supply risk.
With the EU currently dependent on over 80% of its tungsten imports from China, Borralha represents a rare and strategic opportunity to develop a secure, domestic, and NATO-aligned supply source. As Allied continues to advance drilling, resource expansion, and economic studies, Borralha is poised to play a central role in reshaping Europe's tungsten landscape-supporting both decarbonization technologies and defense-industrial resilience.
Understanding Tungsten
To understand tungsten, it is critical to understand the difference between wolframite tungsten mineralization and scheelite tungsten mineralization. Scheelite often reports higher grades but is typically more costly and complex to process, requiring flotation methods with higher capital and operating expenditures and lower recoveries.i In contrast, wolframite can be processed more efficiently using gravity and magnetic separation, resulting in lower costs and higher recoveries, making lower grades economically viable in wolframite deposits. For example, a lower grade wolframite deposit can be more attractive than a slightly higher grade scheelite deposit.ii
It is also important to recognize that China, Russia, and North Korea control approximately 87% of the world's tungsten supply, using cheap labor and minimal environmental standards in authoritarian regimes.iii As a result, production costs and grades in these countries are not comparable to Western projects, which operate under higher labor, ESG, and energy cost structures. Evaluating projects outside these regions provides a realistic benchmark for what grades and intercepts are economically viable while supporting secure, NATO-aligned supply chains.
For Allied, this context is significant. Allied's operations in secure jurisdictions align with Western critical mineral needs, avoiding geopolitical risks associated with China and Russia while positioning the Company to benefit from growing tungsten demand across defense, aerospace, and electrification sectors. Allied's wolframite tungsten mineralization and secure location position it as a strategic and responsible tungsten exploration company, well placed to take advantage of a rising-demand market. iv
About Allied Critical Metals Inc.
Allied Critical Metals Inc. (CSE: ACM) (OTCQB: ACMIF) (FSE:0VJ0) is a Canadian-based mining company focused on the expansion and revitalization of its 100% owned past producing Borralha Tungsten Project and the Vila Verde Tungsten Project in northern Portugal with advantageous wolframite tungsten mineralization. Tungsten has been designated a critical metal by the United States and other western countries, as they are aggressively seeking friendly sources of this unique metal. Currently, China, Russia and North Korea represent approximately 86% of the total global supply and reserves. Tungsten is used in a variety of industries such as defense, automotive, manufacturing, electronics, and energy.
ON BEHALF OF THE BOARD OF DIRECTORS
"Roy Bonnell"
Roy Bonnell
CEO and Director
Please visit our website at www.alliedcritical.com.
Also visit us at:
LinkedIn: https://www.linkedin.com/company/allied-critical-metals-inc
X: https://x.com/@alliedcritical/
Instagram: https://www.instagram.com/alliedcriticalmetals/
The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Information
This news release contains "forward-looking statements", including with respect to the use of proceeds. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company's management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the Company's Listing Statement and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under the Company's profile at www.sedarplus.ca ). Examples of forward-looking statements in this news release include, but are not limited to, statements regarding the proposed timeline and use of proceeds for exploration and development of the Company's mineral projects as described in the Company's Listing Statement, news releases, and corporate presentations. Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements and reference should also be made to the Company's Listing Statement dated April 23, 2025 and news release dated May 16, 2025, and the documents incorporated by reference therein, filed under its SEDAR+ profile at www.sedarplus.ca for a description of additional risk factors. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
iInternational Tungsten Industry Association (ITIA). (2023). Tungsten: Global industry, markets & outlook. Retrieved from https://www.itia.info
ii International Tungsten Industry Association (ITIA). (2023). Tungsten: Global industry, markets & outlook. Retrieved from https://www.itia.info
iii International Tungsten Industry Association (ITIA). (2023). Tungsten: Global industry, markets & outlook. Retrieved from https://www.itia.info
iv International Tungsten Industry Association (ITIA). (2023). Tungsten: Global industry, markets & outlook. Retrieved from https://www.itia.info
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268354
Aviat will address the growing need for multi-Gigabit 5G access use cases in North America with a complete solution portfolio
, /PRNewswire/ -- Aviat Networks, Inc. (NASDAQ: AVNW), the expert in wireless transport and access solutions, today announced a partnership with Intracom Telecom, a global technology systems and solutions provider, to deliver Fixed Wireless Access (FWA) technology that leverages the high-capacity 28 and 39 GHz millimeter wave (mmWave) bands, conforming to FCC requirements for mmWave bands intended for 5G use.
Aviat will initially focus on select North American service providers to address the growing need for multi-Gigabit consumer and enterprise 5G use cases as an alternative to the high cost, delays and complexity of using fiber, but with fiber-like performance. In addition, Aviat will offer software solutions along with a comprehensive set of design, planning, deployment and support services thanks to its extensive presence in North America.
Intracom Telecom's WiBAS G5 platform is the only commercially available point-to-multipoint FWA solution operating in the 28 and 39 GHz mmWave bands that can address the growing demand for high-capacity Fixed Wireless Access, cost effectively delivering over 22Gbps from the same base station site, using Multi-User MIMO and Hybrid Massive Beamforming, over distances of up to 5 miles and more.
"We are very excited at this significant opportunity to extend our wireless expertise to provide advanced mmWave FWA solutions," Pete Smith, CEO of Aviat Networks said, "Wireless can be deployed rapidly and cost effectively, and is perfectly suited to support high speed connectivity combined with excellent reliability."
"I am very proud of Intracom Telecom's R&D team for creating a solution that sets a new benchmark for FWA. Through this strategic partnership with Aviat Networks, we're excited to help U.S. operators accelerate broadband expansion and deliver a true multi-gigabit experience, and more, over wireless," said Kartlos Edilashvili, CEO of Intracom Telecom.
About Aviat Networks
Aviat is the leading expert in wireless transport and access solutions and works to provide dependable products, services and support to its customers. With more than one million systems sold into 170 countries worldwide, communications service providers and private network operators including state/local government, utility, federal government and defense organizations trust Aviat with their critical applications. Coupled with a long history of microwave innovations, Aviat provides a comprehensive suite of localized professional and support services enabling customers to drastically simplify both their networks and their lives. For more than 70 years, the experts at Aviat have delivered high performance products, simplified operations, and the best overall customer experience. Aviat is headquartered in Austin, Texas. For more information, visit www.aviatnetworks.com or connect with Aviat Networks on LinkedIn and Facebook.
About Intracom Telecom
Intracom Telecom is a global technology systems and solutions provider operating for over 45 years in the market. The company is the benchmark in fixed wireless access, and it successfully innovates in the wireless access & transmission field. Furthermore, the company offers a comprehensive software solutions portfolio and a complete range of ICT services. Intracom Telecom serves telecom operators, public authorities and large public and private enterprises. The Group maintains its own R&D and production facilities, operates subsidiaries worldwide and has been active in the North American market since 2001, through its subsidiary, Intracom Telecom USA, based in Atlanta, Georgia. For more information, visit www.intracom-telecom.com
Aviat Networks Media Contact: Stuart Little, [email protected]
Aviat Networks Investor Relations Contact: Andrew Fredrickson, [email protected]
Intracom Telecom Media Contact: Alex Tarnaris, [email protected]
SOURCE Aviat Networks, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Company Receives TSX Approval for Renewal of Normal Course Issuer Bid
, /PRNewswire/ - Ovintiv Inc. (NYSE: OVV), (TSX: OVV) today announced it has received regulatory approvals for the renewal of its share buy-back program. This action is consistent with Ovintiv's capital allocation framework, which returns at least 50 percent of post base dividend Non-GAAP Free Cash Flow to shareholders.
Ovintiv Renews Annual Share Buy-Back Program (CNW Group/Ovintiv Inc.)
The Toronto Stock Exchange ("TSX") has accepted Ovintiv's notice of intention to renew its normal course issuer bid ("NCIB") to purchase up to 22,287,709 common shares during the 12-month period commencing October 3, 2025, and ending October 2, 2026. The number of shares authorized for purchase represents 10 percent of Ovintiv's public float as of September 26, 2025, as calculated pursuant to TSX rules. Purchases will be made on the open market through the facilities of the TSX, New York Stock Exchange ("NYSE"), other designated exchanges and/or alternative trading systems in Canada and the United States at the market price at the time of acquisition, as well as by other means permitted by stock exchange rules and securities laws including Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
Ovintiv has also renewed its automatic share purchase plan ("ASPP") allowing it to purchase common shares under the NCIB when Ovintiv would ordinarily not be permitted to purchase shares due to regulatory restrictions and customary self-imposed blackout periods. Pursuant to the ASPP, Ovintiv will provide instructions during non-blackout periods to its designated broker, which may not be varied or suspended during the blackout period. Purchases by Ovintiv's designated broker will be in accordance with applicable stock exchange rules and securities laws and the terms of the ASPP. All purchases made under the ASPP are included in computing the number of common shares purchased under the NCIB. The ASPP has been pre-cleared as required by the TSX.
The actual number of common shares that may be purchased under the NCIB and the timing of any such purchases will be determined by Ovintiv. The average daily trading volume through the facilities of the TSX, excluding purchases made on such facilities, for the six months ended August 31, 2025 was 185,256 common shares. Consequently, daily purchases through the facilities of the TSX will be limited to 46,314 common shares, other than block purchase exceptions. Purchases over the NYSE will be made in compliance with the volume limitations in Rule 10b-18 in relation to average daily trading volume and block trades. All common shares acquired by Ovintiv under the NCIB may be cancelled or returned to treasury as authorized but unissued shares.
Pursuant to its existing NCIB, under which Ovintiv received approval from the TSX to purchase up to 25,920,545 common shares during the 12-month period commencing October 3, 2024 and ending October 2, 2025, Ovintiv has purchased 7,836,011 common shares on the TSX, NYSE and alternative trading systems at a weighted average purchase price of US$38.80 per common share.
On June 5, 2025, Ovintiv renewed its exemption order (the "NCIB Exemption") from applicable Canadian regulators, permitting Ovintiv to make repurchases under the NCIB through the facilities of the NYSE and other United States-based trading systems in excess of 5 percent of Ovintiv's outstanding number of shares, the maximum allowable under applicable Canadian securities laws absent an exemption. The NCIB Exemption allows Ovintiv to repurchase up to 10 percent of Ovintiv's public float on such U.S. marketplaces provided that Ovintiv's aggregate repurchases on all marketplaces do not exceed this amount over the 12-month period of the NCIB, which is consistent with the maximum number of shares Ovintiv is able to purchase under the NCIB. The other conditions to the NCIB Exemption are outlined in Ovintiv's 2025 second quarter report on Form 10-Q filed on EDGAR and SEDAR+.
ADVISORY REGARDING FORWARD-LOOKING STATEMENTS - This news release contains certain forward-looking statements or information (collectively, "FLS") within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. FLS include: the planned share repurchase program, including the amount and number of shares to be acquired, treatment of such shares following purchase, anticipated timeframe, method and location of purchases, announced capital framework; and benefits of the NCIB.
Readers are cautioned against unduly relying on FLS which, by their nature, involve numerous assumptions, risks and uncertainties that may cause such statements not to occur, or results to differ materially from those expressed or implied. These assumptions include: future commodity prices and differentials; foreign exchange rates; ability to access cash, credit facilities and shelf prospectuses; and expectations and projections made in light of, and generally consistent with, Ovintiv's historical experience and its perception of historical trends, including with respect to the pace of technological development, benefits achieved and general industry expectations.
Risks and uncertainties that may affect these business outcomes include: ability to generate sufficient cash flow to meet obligations and fund the NCIB; commodity price volatility; variability in the amount, number of shares, method, location and timing of purchases, if any, pursuant to the NCIB; fluctuations in currency and interest rates; and other risks and uncertainties impacting Ovintiv's business, as described in its most recent Annual Report on Form 10-K and as described from time to time in Ovintiv's other periodic filings as filed on EDGAR and SEDAR+.
Although Ovintiv believes the expectations represented by such FLS are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned that the assumptions, risks and uncertainties referenced above are not exhaustive. FLS are made as of the date of this news release and, except as required by law, Ovintiv undertakes no obligation to update publicly or revise any FLS. FLS contained in this news release are expressly qualified by these cautionary statements.
Further information on Ovintiv is available on the company's website, www.ovintiv.com, or by contacting:
Investor contact:
(888) 525-0304
Media contact:
(403) 645-2252
SOURCE Ovintiv Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.Eupraxia intends to expand the EP-104GI development program, including increasing the number of patients in the Phase 2b portion of RESOLVE from 60 to at least 120 patients.Eupraxia intends to initiate a clinical trial for an additional market-expanding GI indication in the first half of 2026.Eupraxia will host a webinar on October 1st at 8am PDT to provide additional information. The live webinar is available at: https://lifescievents.com/event/fk30t7wg2n/ VICTORIA, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, today provided an operational update on the development of EP-104GI, including reporting data from patients in Cohort 9 of the dose escalation portion of the RESOLVE trial, the first time that patients received an 8mg dose per injection.
“We believe our recent financing, combined with our latest clinical trial results, underscores both the medical and investment communities’ confidence in EP-104GI. The strong efficacy trend observed in previous cohorts – the more drug we deliver to the tissue, the better the results we observe – has continued in Cohort 9. Combined with the absence of any Serious Adverse Events or cases of candidiasis, this strongly suggests that an 8mg dose per injection is the optimal second dose to test in our Phase 2b trial”, said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We believe EP-104GI has the potential to significantly improve upon the current standard of care, as the clinical efficacy outcomes and improvements in tissue health reported so far are well beyond the published results for the leading currently approved therapies. With the capital raised, we are well-positioned to expand our Phase 2 study, prepare for a robust Phase 3 program, and pursue additional clinical indications, subject to discussions with FDA, all with a runway extending well into 2028”.
Key Findings from the 8mg Per Injection Dose Group in the Dose Escalation Portion of the RESOLVE Trial
The corporate presentation on the Company’s website has been updated to reflect the additional data described below.
Clinical Remission1: Rapid and meaningful induction of clinical remission observed as measured by the Straumann Dysphagia Index (“SDI”)2Tissue Health and Eosinophil Reduction: Greatest improvements to date in EoEHSS (Eosinophilic Esophagitis Histological Scoring System) scores, with the greatest percentage of biopsy sites in remission (≤6 eos/hpf)3Correlation to Outcomes: Across all cohorts, when more drug is delivered into the tissue, greater disease resolution and eosinophil reduction is observedDurability: Long-term data continues to show patients maintaining clinical benefit, tissue health, and tolerabilitySafety Outcomes: Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose
Key Changes to The Phase 2b RESOLVE Trial
Based on the positive safety and efficacy results from Cohort 9 in the open-label dose escalation (Phase 1b/2a study), Eupraxia expects to select the 8 mg/per injection & 20 injections per administration (for a total for 160 mg per patient) as the second active dose level for the Phase 2b portion of the RESOLVE trial. The dose level has been cleared by the RESOLVE Safety Committee and endorsed by members of the Eupraxia Clinical Advisory Board.Eupraxia intends to increase the size of the Phase 2b portion of the RESOLVE Trial to a minimum of 40 patients per dose group. The total number of patients enrolled is expected to increase from 60 to at least 120.The increase in size of the Phase 2b trial will provide the following benefits: Greater statistical power to the primary and all key secondary endpointsLarger safety databaseImproved potential of obtaining breakthrough statusHigher probability of needing to perform only a single Phase 3 pivotal trialImproved ability to select an optimized dose for Phase 3 for safety, efficacy and durability Expanded Plans for EP-104GI and Other New Drug Candidate(s)
In addition to increasing the size of the RESOLVE study, Eupraxia intends to use proceeds from the recent financing to expand the non-clinical and clinical program for EP-104GI, subject to discussions with FDA, with the aim of increasing the future market size of the program. This includes:
Development of additional indications for EP-104GI in the GI field; the Company plans to dose first patients in the first half of 2026.The Company is currently considering indications where localized treatment would provide maximum benefit such as fibrostenotic Crohn’s, treatment of benign esophageal strictures, and the prevention of strictures in Barrett’s esophagus.Completion of non-clinical work to enable repeat dosing and inclusion of adolescent patients in the Phase 3 program.Development work of applications for Diffusphere™ with other Active Pharmaceutical Ingredients (APIs) other than fluticasone propionate About the RESOLVE Trial
The Phase 1b/2a part of the RESOLVE trial, is a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically confirmed active EoE. The treatment is administered as a single dose via 4 to 20 esophageal wall injections, with dose escalations modifying either the dose per site and/or the number of sites. Participants were followed for up to 24 weeks (4x1mg, 8x1mg, 8x2.5mg and 12x2.5mg) or 52 weeks (12x4mg and subsequent ongoing dose levels). Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in Q4 2025.
The Phase 2b part of the RESOLVE trial, a randomized placebo-controlled study of EP-104GI, is currently recruiting with the first clinical dose of 120mg (20 x 6mg). The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q3 2026.
Notes
Clinical remission is defined as a reduction of at least 3 points on the SDI scale. Achieving clinical remission is a positive outcome for the RESOLVE trial.SDI is a patient-reported outcome score that uses a seven-day recall measuring dysphagia (trouble swallowing) severity and frequency. A reduction in SDI is a positive outcome for the RESOLVE trial.In the EoEHSS, grade indicates the severity of each of the eight histologic features assessed by the EoEHSS while stage indicates their extent. For the RESOLVE trial, these features include inflammation, increased cell production in a normal tissue or organ, and fibrosis, also known as fibrotic scarring, and five other features. A reduction in EoEHSS is a positive outcome for the RESOLVE trial.
About Eosinophilic Esophagitis (EoE)
EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market research from Clearview Healthcare Partners, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental health issues, compounding the disease burden of EoE for both the healthcare system and the individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company’s expected timing of reporting additional data from the RESOLVE trial in Q4 2025; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company’s product candidates; the results gathered from studies and trials of Eupraxia's product candidates and the expected timing thereof; the Company’s plans to expand the EP-104GI developmental program, including the increase in the number of patients in the Phase 2b portion of RESOLVE and dosing level to be selected, and the timing and expected benefits thereof; the potential for the Company’s technology to impact the drug delivery process; the expected use of proceeds of the Company’s recent financing; potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302 [email protected]
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856 [email protected]
ROANOKE, Va., Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2075 per share on the Company’s common stock. The dividend will be paid on November 3, 2025 to shareholders of record on October 17, 2025. This is the Company’s 326th consecutive quarterly cash dividend.
RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Midstream, L.L.C.
The statements in this release that are not historical facts constitute “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause the Company’s actual results and experience to differ materially from any expectations expressed in the Company’s forward-looking statements, regarding customer growth, infrastructure investment and margins. These risks and uncertainties include gas prices and supply, geopolitical considerations and regulatory and legal challenges along with risks included under Item 1-A in the Company’s fiscal 2024 Form 10-K. Forward-looking statements reflect the Company’s current expectations only as of the date they are made. The Company assumes no duty to update these statements should expectations change or actual results differ from current expectations except as required by applicable laws and regulations.
Past performance is not necessarily a predictor of future results.
Contact: Timothy J. Mulvaney Vice President, Treasurer and CFO Telephone: 540-777-3997
2025-09-29 21:122mo ago
2025-09-29 17:002mo ago
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2025.
The 2025 half-year financial statements were subject to a limited review by the Company’s statutory auditors and approved by the Board of Directors on September 26, 2025. The full interim financial report is available on the Company’s website in the Investors section.
“We have rigorously maintained financial discipline in the first half of 2025, achieving an 8% reduction in cash outflow compared to the prior year period through optimized cash management. The €3.7 million financing we completed last week has extended our cash runway, providing us with sufficient funds until the expected decision of the ANSM with regard to the French Early Access Program,” noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. “While the funds raised position us well for the coming months, we may consider additional capital before year-end, should the evaluation of the dose-ranging study requested by the French authorities extend into the end of Q4 2025.”
2025 Half-Year Financial Results (IFRS)
In million euros
H1 2024
H1 2025
Revenues
1.1
(0.2)
Other income
0.6
0.3
Operating income
1.7
0.1
Research and development expenses
(6.3)
(4.3)
Sales, medical and marketing expenses
(0.3)
(0.2)
General and administrative expenses
(2.6)
(2.3)
Operating profit (loss)
(7.4)
(6.8)
Financial income (loss)
1.6
(0.2)
Net income (loss)
(5.8)
(7.0)
EPS (in € per share)
(0.07)
(0.05)
Net cash flows from operating activities
(7.3)
(2.5)
Net cash flows from investment activities
0.0
0.0
Net cash flows from financing activities
12.1
0.3
Net cash flows
+4.8
(2.2)
Cash and cash equivalents at closing
6.9
0.3
Operating income decreased to €0.04 million from €1.7 million over the period. In the first half of 2025, income mainly reflects the Research Tax Credit (CIR), partly offset by the accounting impact of discounting potential rebate obligations linked to ATUs (GS010/LUMEVOQ®, 2019–2022). These obligations were re-estimated in June 2024, following a revised timeline for the final reimbursement negotiations, which impacted revenue. There was no change in the estimate during the first half of 2025.
The Company has collected the research tax credit (Crédit d’Impôt Recherche), amounting to €0.3 million in the first half of 2025, compared to €0.6 million in the first half of 2024. As of June 30, 2025, the Research Tax Credit (CIR), is lower compared with the same period last year, as eligible expenses are reduced. The Company is expecting to collect an additional €0.2 million in early October 2025.
The main spending was related to preparation of the dose-ranging study requested by the ANSM in the context of assessment of the French Early Access program. The protocol was submitted to the ASNM in mid-August 2025 and is being reviewed under a clear regulatory timeline.
Research and development expenses decreased by 31.8%, or €2.0 million, and amounted to €4.3 million in the first half of 2025 compared to €6.3 million a year earlier. This decrease was essentially driven by a sharp reduction in R&D spending, achieved by focussing mainly on the technology transfer of GS010 manufacturing to our new manufacturing partner, Catalent, Inc., and on essential costs related to preparation of the dose-ranging study.
Sales, medical and marketing expenses decreased by 12.8% in H1 2025 and amounted to €0.2 million in the first half of 2025 compared to €0.3 million a year earlier, reflecting disciplined cost management.
General and administrative expenses fell by 10% in H1 2025, amounting €2.3 million compared to €2.6 million a year earlier, reflecting disciplined cost management. Personnel costs increased following the hiring of a CFO in September 2024, a function that had been outsourced in H1 2024, while professional fees decreased by 38.1%, highlighting the company’s effective monitoring of spending.
Operating loss decreased by 8.3%, or €0.6 million, in the first half of 2025, amounting to €(6.8) million compared to €(7.4) million over the same period in 2024. This decrease reflects trends in operating income; R&D expenses; sales, medical and marketing expenses; and G&A expenses as discussed above, partially offset by the reduction in the research tax credit.
Financial income in the first half of 2025 amounted to €(0.2) million compared to €1.6 million over the same period in 2024. In 2024, the financial income is essentially explained by the renegotiation of our financial obligations and the change in derivative financial instrument fair value.
Net loss for the first half of 2025 increased to €(7.0) million compared to €(5.8) million in the first half of 2024. The loss per share (based on the weighted average number of shares outstanding over the period) amounted to €(0.05) and €(0.07) for the first half of 2025 and 2024, respectively.
Net cash flows from operating activities in the first half of 2025 and in 2024 were €(2.5) million and €(7.3) million, respectively. The sharp decrease in 2025 is driven mainly by the decrease in operating expenses. The decrease in income also contributed.
Net cash flows from investment activities amounted to €0.0 million in the first half of 2025 and in 2024, driven mainly by the activity of the Company’s liquidity contract.
Net cash flows from financing activities amounted to €0.3 million in the first half of 2025, compared to €12.1 million in the same period of 2025. This reflects capital increases of €0.8 million in 2025 versus €9.3 million in 2024, in line with the company’s financing needs and the timing of fundraising activities.
Cash and cash equivalents amounted to €0.3 million as of June 30, 2025, compared to €2.1 million twelve months earlier.
Other Financial Updates
Cash runway
By the end of September 2025, the Company anticipates having cash on hand amounting to a minimum of €3.0 million, taking into account:
The financing completed on July 1 and July 18, 2025, which raised approximately €4.5 million gross
The financing secured on September 25, 2025, totaling €3.7 million through equity with 100% warrant coverage from existing investors; the delivery of shares and payments are scheduled for September 30, 2025
The September Heights Capital Scheduled Installment Payment paid in cash for €0.7 million
Based on current operations, plans, and assumptions, the September funding is expected to extend the Company's operational runway into late Q4 2025. If the French Early Access Program launches as expected, the resulting revenue would further extend the cash runway to the end of May 2026. However, should the regulatory decision for the requested dose-ranging study be delayed until the end of Q4 2025, the Company may require additional financing before year-end.
In June 2025, the Company reached an agreement with the ANSM (the French medicines agency) to expeditiously consider the French Early Access Program following approval of a dose-ranging study. The study protocol was submitted in August 2025, with the regulatory decision expected by the Company between October and November 2025, based on well-defined regulatory timelines. In case of a positive decision, this should enable the launch of revenue-generating programs by year-end.
The Company is actively pursuing opportunities to out-license GS010 in markets outside the USA and Europe, while exploring paid Early Access Programs worldwide. These EAPs and out-license opportunities will allow non-dilutive revenue to be generated, which will partially self-fund subsequent development phases and reduce reliance on equity financing.
Management’s Plans and Financing Strategy
Revenue-Driven Runway Extension:
If the ANSM provides a green light to open the French Early Access Program in Q4 2025, it is expected to generate enough revenue to extend operations until end of May of 2026. This will significantly improve the company's liquidity position and provide additional time to secure long-term funding. In the event of an opening in late 2025 or prolonged assessment, the company may require additional financing before the end of the year.
Medium-term Funding Strategy (Beyond May 2026):
The Company has strategically sequenced its operational milestones to create multiple value inflection points and diversified funding opportunities:
Non-dilutive Sources:
Early Access Program (EAP) reimbursements worldwide
Licensing and partnership agreements, with enhanced attractiveness as manufacturing and early market access capabilities are demonstrated
Dilutive Sources:
Additional equity raises, timed to align with operational milestones that reduce execution risk
Strategic partnerships or merger and acquisition opportunities
This phased approach ensures that each operational success enhances the Company’s ability to secure funding for subsequent development phases while progressively reducing dependence on equity markets through revenue generation.
Going Concern Assessment
Key Assumptions
Based on current operations and plans, the Board has prepared the financial statements on a going concern basis based on the following critical assumptions:
Anticipated opening of the French Early Access program in Q4 2025, generating revenue to help extend operations to end of May 2026. The company may need small complementary financing before the end of the year, should the expected authorization of the requested dose ranging study extend until the end of Q4 2025.
Securing additional long-term funding (both non-dilutive and dilutive) before mid-2026 to sustain operations through Phase III clinical development and regulatory submission phases
The respect of payment agreements with suppliers
The settlement of Height’s redemption installments (€0.7M per quarter) in shares rather than cash, which the company is entitled to enforce, provided that the company’s share price remains above the contractual floor limit
Material Uncertainty
While the Company believes in its ability to raise additional funds or realize M&A opportunities, no assurance can be given that these objectives will be achieved or that sufficient funds will be secured at acceptable terms. Failure to secure adequate funding could require the Company to severely modify its operating plans, impair its ability to realize its assets and pay its liabilities in the normal course of business, or be forced to enter into insolvency proceedings or cease its operations in whole or in part. Therefore, substantial doubt exists regarding the Company's ability to continue as a going concern.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the completion expected proceeds and anticipated use of proceeds of the Fundraising; the anticipated cash runway of the Company; and future expectations, plans and prospects of the Company. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed Fundraising and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the filings the Company makes with the AMF from time to time. The Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
2025-09-29 21:122mo ago
2025-09-29 17:032mo ago
NewtekOne, Inc. Declares Dividend on Series B Preferred Shares
BOCA RATON, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“the Company”) (NASDAQ: NEWT) has declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) in the amount of $9.44 per Preferred Share, or $0.2361 per depositary share, which is equivalent to 1/40th of the dividend on the Preferred Shares, payable on October 1, 2025 to holders of record as of September 29, 2025. This initial dividend payment on the Preferred Shares is pro-rated for the initial dividend period from the date of the issuance of the Preferred Shares on August 20, 2025.
About NewtekOne, Inc.
NewtekOne®, Your Business Solutions Company®, is a financial holding company, which along with its bank and non-bank consolidated subsidiaries (collectively, “NewtekOne”), provides a wide range of business and financial solutions under the Newtek® brand to independent business owners. Since 1999, NewtekOne has provided state-of-the-art, cost-efficient products and services and efficient business strategies to independent business owners across all 50 states to help them grow their sales, control their expenses, and reduce their risk.
NewtekOne’s and its subsidiaries’ business and financial solutions include: banking (Newtek Bank, N.A.), Business Lending, SBA Lending Solutions, Electronic Payment Processing, eCommerce, Accounts Receivable Financing & Inventory Financing and Insurance Solutions, Web Services, and Payroll and Benefits Solutions. In addition, NewtekOne offers its clients the Technology Solutions (Cloud Computing, Data Backup, Storage and Retrieval, IT Consulting and Web Services) provided by Intelligent Protection Management Corp. (IPM.com).
Newtek®, NewtekOne®, Newtek Bank®, National Association, Your Business Solutions Company®, One Solution for All Your Business Needs® and Newtek Advantage are registered trademarks of NewtekOne, Inc.
Note Regarding Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the rules and regulations of the Private Securities Litigation and Reform Act of 1995 are based on the current beliefs and expectations of NewtekOne's management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. See “Note Regarding Forward-Looking Statements” and the sections entitled “Risk Factors” in our filings with the Securities and Exchange Commission which are available on NewtekOne's website (https://investor.newtekbusinessservices.com/sec-filings) and on the Securities and Exchange Commission’s website (www.sec.gov). Any forward-looking statements made by or on behalf of NewtekOne speak only as to the date they are made, and NewtekOne does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.
Randy Smallwood, CEO of Wheaton Precious Metals, joins CNBC's Closing Bell Overtime to discuss how the company is capitalizing on rising gold prices, the advantages of its streaming model versus traditional mining, why Wheaton sees long-term value in precious metals, and more.
2025-09-29 21:122mo ago
2025-09-29 17:052mo ago
Green Bridge Metals Announces Non-Brokered Private Placement
VANCOUVER, BC / ACCESS Newswire / September 29, 2025 / Green Bridge Metals Corporation (CSE:GRBM)(OTCQB:GBMCF)(FWB:J48)(WKN:A3EW4S) ("Green Bridge" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 66,666,667 units of the Company (the "Units") at a price of $0.09 per Unit, for aggregate gross proceeds of up to $6,000,000. Each Unit shall consist of one common share (each a "Share") and one-half (1/2) of one common share purchase warrant (each whole warrant, a "Warrant"), with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of $0.15 for a period of three (3) years.
2025-09-29 21:122mo ago
2025-09-29 17:052mo ago
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize the advancement of its three ADC programs and research and development collaborations. The restructuring, along with certain expected near-term milestone payments, is expected to extend the Company’s runway into at least mid-2027, after the planned announcement of initial clinical data from STRO-004, its next-generation Tissue Factor-targeting exatecan ADC, and the initiation of clinical studies for at least one of Sutro’s additional ADC programs. This restructuring will result in a planned workforce reduction of approximately one-third of employees.
“After continued review of our business and pipeline priorities, we have identified and are implementing further operational efficiencies to focus our resources where they will have the greatest impact—advancing Sutro’s ADC portfolio to deliver transformative therapies for patients with cancer. We remain on track to advance STRO-004 into the clinic this year, with initial data expected in 2026,” said Jane Chung, Sutro’s Chief Executive Officer. “Importantly, these changes extend our expected financial runway through critical milestones and strengthen our ability to create value for both patients and shareholders. We are deeply grateful to the dedicated employees who have contributed to Sutro’s progress, and their work will remain foundational to our mission moving forward.”
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, clinical results, trial initiation, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company’s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company’s product candidates; the timing and receipt of anticipated future milestone payments; the Company’s expected cash runway; and the expected costs and cost reductions associated with the restructuring. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact Data
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
Media Contact
Amy Bonanno
Lyra Strategic Advisory
2025-09-29 21:122mo ago
2025-09-29 17:052mo ago
VerticalScope Taps TollBit to Unlock AI License Revenue and Protect Community Content
TORONTO--(BUSINESS WIRE)--VerticalScope Holdings Inc. (“VerticalScope” or the “Company”) (TSX: FORA; OTCQX: VFORF), a technology company that has built and operates a cloud-based digital platform for online enthusiast communities, today announced a partnership with TollBit, an innovative platform that connects online platforms and publishers with AI companies seeking to license high-quality data. This collaboration represents an important step in VerticalScope’s strategy to monetize its unique corpus of authentic content while protecting the integrity and value of its forums in the era of generative AI.
This partnership represents an important step in positioning VerticalScope for an AI-first content discovery experience.
Share
With more than 2.3 billion posts across 1,200 communities, VerticalScope owns one of the internet’s largest structured datasets of authentic, evergreen community content. By partnering with TollBit, VerticalScope will establish a scalable framework for licensing its content to AI and LLM providers, with the goal of ensuring fair value exchange and enabling new monetization streams.
Chris Goodridge, CEO of VerticalScope, commented: “This partnership represents an important step in positioning VerticalScope for an AI-first content discovery experience. Our communities generate unique, high-intent knowledge that is key for AI training and retrieval-augmented generation. By working with TollBit, we’re creating a fair and transparent licensing model that ensures our communities remain a trusted source of human expertise while positioning VerticalScope to unlock a new revenue stream. I’m excited to see how this partnership strengthens our platform and accelerates our ability to diversify and grow.”
Toshit Panigrahi, CEO of TollBit, said: “TollBit was built to help platforms like VerticalScope capture the value of their content in an AI-driven world. VerticalScope’s communities are an incredibly deep repository of authentic, domain-specific knowledge that AI systems need but can’t replicate. Together, we’re creating a model where platforms and publishers are compensated fairly, AI companies gain access to high-quality data, and community members see their contributions valued and protected, ensuring these forums remain vibrant resources for enthusiasts. This is exactly the type of partnership TollBit was designed to power.”
As the internet is experiencing a surge in AI-driven traffic, TollBit enables publishers to convert scraping into authorized, revenue-generating access by installing a “toll booth” on websites that monitors AI traffic, authenticates it, and monetizes content requests. This partnership reflects VerticalScope’s commitment to safeguarding community contributions while unlocking new revenue opportunities that support community growth in this evolving AI landscape.
About VerticalScope Holdings Inc.
Founded in 1999 and headquartered in Toronto, Ontario, VerticalScope is a technology company that has built and operates a cloud-based digital platform for online enthusiast communities in high consumer spending categories. VerticalScope's mission is to enable people with common interests to connect, explore their passions, and share knowledge about the things they love. Through targeted acquisitions and development, VerticalScope has built a portfolio of over 1,200 online communities and approximately 100 million monthly active users.
About TollBit
TollBit is a platform that enables a fair exchange of value between AI companies and websites. By essentially installing a toll booth on websites, TollBit allows them to monitor bot traffic and monetize their data and content, while offering AI agents and applications an easy way to pay directly for that content. The platform seeks to address the shifting economics of content creation in the AI era by reducing the legal uncertainties of scraping and protecting the health of the entire content ecosystem.
Forward-Looking Statements
This news release contains forward-looking information within the meaning of applicable securities legislation that reflects the Company's current expectations regarding future events. When used in this news release, words such as “should”, “could”, “intended”, “expect”, “plan” or “believe” and similar expressions indicate forward-looking statements. Forward-looking information, including the Company’s plans for organic growth, potential new revenue streams from AI licensing, strategies related to the monetization of community content, business strategy, growth strategies, addressable markets, operations, plans and objectives, is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Although the Company believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurances can be given that actual results will be consistent with these forward-looking statements. Such risks and uncertainties include the factors discussed under "Risk Factors" in the Company’s Annual Information Form dated March 31, 2025, which is available on the Company’s profile on SEDAR Plus at https://sedarplus.ca. Actual results could differ materially from those projected herein. VerticalScope does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws.
SOURCE VerticalScope Holdings Inc.
More News From VerticalScope Holdings Inc.
2025-09-29 21:122mo ago
2025-09-29 17:072mo ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Quanex Building Products Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NX
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Quanex Building Products Corporation (NYSE: NX) between December 12, 2024 and September 5, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025.
SO WHAT: If you purchased Quanex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Quanex’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, Quanex’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) as a result of the foregoing, Quanex was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) Quanex had previously identified the foregoing issues; and (5) as a result of the foregoing, defendants’ positive statements about Quanex’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Quanex class action, go to https://rosenlegal.com/submit-form/?case_id=45157 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
2025-09-29 21:122mo ago
2025-09-29 17:092mo ago
Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Chasing after others' buying can sometimes work, as long as investors have their own unique reason to buy, founded upon sound fundamentals. Recently, Cathie Wood from Ark Innovation ETF NYSEARCA: ARKK chose to expand her horizons beyond the United States technology sector, finding opportunities for undervalued blue chips in China and deploying a few million into some of the biggest names in Asia's powerhouse.
2025-09-29 20:122mo ago
2025-09-29 15:032mo ago
BlackRock's ETF IBIT surpasses Deribit as top Bitcoin options venue globally: Bloomberg
Options growth on IBIT highlights shifting institutional strategies as traditional finance deepens its presence in digital asset markets.
Photo: Jeenah Moon
Key Takeaways
BlackRock's IBIT ETF is now the largest global Bitcoin options trading venue, overtaking Deribit.
IBIT holds about $84.6 billion in assets, making it the leading Bitcoin ETF by capital.
BlackRock’s spot Bitcoin ETF, IBIT, has overtaken Deribit as the world’s largest Bitcoin options trading venue, Bloomberg reported today.
The milestone reflects Wall Street’s growing dominance in crypto derivatives markets. IBIT holds approximately $84.6 billion in assets, making it the largest Bitcoin ETF by capital.
Deribit, a crypto derivatives exchange, previously led global Bitcoin options trading volume before being displaced by BlackRock’s ETF product.
Options tied to IBIT have been surging, contributing to ETF-led price discovery and capturing a growing share of total crypto options volume. The development comes as BlackRock filed for a premium income ETF that would generate yield by selling covered calls on IBIT holdings.
BlackRock has been expanding its Bitcoin exposure across multiple products. The asset manager increased its Bitcoin allocation by 38% in its $17.1 billion Global Allocation Fund, holding over 1 million IBIT shares valued at $66.4 million as of July 2025.
As of September 28, Bitmine, a leading player in the cryptocurrency sector, reported owning over 2.65 million ethereum, along with other crypto and cash assets totaling $11.6 billion. This revelation highlights Bitmine's significant role in the digital currency ecosystem, with Ethereum being a substantial part of their portfolio.
2025-09-29 20:122mo ago
2025-09-29 15:152mo ago
On-Chain Data Shows Bitcoin Far From Peak as Analyst Maps $240K Bull Case
Analysts reviewing on-chain data suggest Bitcoin remains below euphoric highs, tracking scenarios toward $157k–$300k. The market has shown smaller drawdowns since 2023, with comparisons to gold and support near $100k–$105k shaping the current spot-driven cycle.
2025-09-29 20:122mo ago
2025-09-29 15:162mo ago
Aster DEX Overtakes Hyperliquid With $46B Daily Trading Volume
In one of the most dramatic developments in decentralized finance this year, Aster, a decentralized perpetual exchange, recorded more than $46 billion in daily trading volume on Friday. This milestone briefly pushed it ahead of Hyperliquid, a dominant force in the sector, and signaled a shifting power dynamic in the perpetual trading landscape.
2025-09-29 20:122mo ago
2025-09-29 15:202mo ago
Solana Price Prediction: New Firedancer Upgrade Could Make SOL the Fastest Blockchain – Can SOL Challenge Bitcoin Now?
Solana price prediction has firmed after Firedancer's SIMD-0370 has proposed validator-driven capacity and Alpenglow has targeted 100ms finality. Debate has persisted over centralization risks as price has tested the $200 level with paths toward $255 and $330 if support has held.
2025-09-29 20:122mo ago
2025-09-29 15:232mo ago
SEC Halts Trading of Bitcoin, Ethereum Treasury Firm QMMM After 2,000% Stock Surge
In brief
Digital advertising firm QMMM Holdings announced that it was buying Bitcoin, Ethereum, and Solana earlier this month.
The company's stock has skyrocketed by more than 2,100% over the last month amid the crypto pivot.
The SEC has now halted trading of the stock, and alleges that there may be manipulation at play.
The Securities and Exchange Commission has halted trading of a company after its stock boomed by over 2,000% following a recently announced crypto treasury pivot.
Digital advertising firm QMMM Holdings earlier this month announced a plan to buy Bitcoin, Ethereum, and Solana—causing an explosion in the price of its stock. In September alone, its price has risen by more than 2,100%, according to Yahoo Finance data, finishing Friday at a price of $119.40.
But Wall Street's biggest regulator said Monday that it was suspending trading of the security until October 10 as it investigates "potential manipulation" of the stock.
"The Commission temporarily suspended trading in the securities of QMMM because of potential manipulation in the securities of QMMM effectuated through recommendations, made to investors by unknown persons via social media to purchase the securities of QMMM, which appear to be designed to artificially inflate the price and volume of the securities of QMMM," the statement from the SEC read.
Decrypt reached out to the SEC and QMMM Holdings for comment, but did not immediately receive a response from either party.
Hong Kong-based QMMM Holdings said at the start of the month that its treasury will initially start with $100 million worth of cryptocurrency.
The SEC's announcement comes as regulators pay closer attention to digital asset treasuries—companies that buy cryptocurrency with spare cash. Last week, the Wall Street Journal reported that the SEC and the Financial Industry Regulatory Authority, or FINRA, had contacted companies after identifying unusual trading activity.
A number of companies have bought cryptocurrencies like Bitcoin, Ethereum, and Solana to get better returns for shareholders. Such firms have often seen their share prices soar—albeit sometimes briefly—after announcing crypto treasury pivots.
Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.
2025-09-29 20:122mo ago
2025-09-29 15:302mo ago
Bitcoin rises to around $114,000, recovering some of last week's losses: CNBC Crypto World
On today's episode of CNBC Crypto World, eToro introduces staking for U.S. customers, who can now earn rewards for crypto assets, including Cardano's ADA token, ether, and Solana's SOL token. Plus, the Blockchain Association sends a letter to lawmakers reaffirming the support of the digital assets industry for the GENIUS Act, which is now law in the United States.
2025-09-29 20:122mo ago
2025-09-29 15:342mo ago
Bitcoin Steady At $114,000 While Ethereum, XRP, Dogecoin Push Higher
Coinglass data shows 119,951 traders were liquidated in the past 24 hours for $416.34 million.
In the past 24 hours, top losers include MemeCore (CRYPTO: M), Plasma (CRYPTO: XPL) and Pump. fun (CRYPTO: PUMP).
Notable Developments:
XRP, Solana, Dogecoin ETF Filings Withdrawn As SEC Initiates Shift: Bullish Or Bearish?
BitMine Jumps 5% As Ethereum Treasury Surges Past 2.65 Million ETH
Bitcoin Reclaims $114,000, But Why Does The Fear & Greed Index Show ‘Fear’?
Bitcoin Pops To $114,000 As Strategy Expands BTC Treasury To $47 Billion
REX Shares Drops Three ETFs To Bet Big On Bitcoin Mining, AI Cloud, Stablecoins
SOL Up 3% But $34M Solana Outflows Raise Alarms Ahead Of ETF Decision
Trader Notes: IncomeSharks noted that Bitcoin shook off last week's bearish sentiment, reclaimed support, and is now forming a clean double bottom setup.
Stockmoney Lizards highlighted Bitcoin's MVRV Z-Score, signaling upside potential. He expects a retest before a likely Q4 pump, suggesting room for the market to run.
Michael van de Poppe observed that Bitcoin holding above the 20-Week MA after a corrective week led to a strong upward bounce. He sees this as a possible low for a big breakout ahead.
Ted Pillows pointed out that while open interest jumped by $2 billion today, leverage is building. He notes this could bring volatility and is curious about Bitcoin's reaction to this setup.
Read Next:
Bitcoin Underperforms Ethereum By 60% In Q3: Which Coin WIll Perform Better In Q4?
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
HYPE price prediction has accelerated after Cathie Wood has compared Hyperliquid to early Solana. TVL has risen from ~$154M to >$2.2B, stablecoins have expanded, and an NFT debut has posted high volumes, while price action has tested Fibonacci levels with targets near $52–$53 if support holds.
2025-09-29 20:122mo ago
2025-09-29 15:412mo ago
ZIGChain price jumps 22% as BTCS allocates $30m to ZIG treasury strategy
ZIGChain price jumped double digits to hit highs of $0.11 amid a major digital asset treasury announcement by Europe-based firm BTCS.
Summary
ZIGChain price rose by more than 22% as price broke to highs of $0.11.
The token’s value jumped as BTCS announced a $100 million raise and $30 million allocation to its ZIG digital asset treasury strategy.
ZIGChain, the layer 1 blockchain aimed at the democratization of wealth generation through real-world asset tokenization, saw its native token’s price soar by more than 22% to hit highs near $0.11.
The surge to the intraday high, the highest price level for the altcoin in over a month, came amid an announcement by publicly-traded firm BTCS. In an update, BTCS, the largest European digital asset treasury company, said it had raised $100 million in a new funding round.
BTCS plans to use proceeds of this Series G raise for its crypto treasury strategy, with $30 million going into a ZIGChain (ZIG) treasury strategy.
🚨 Europe’s largest listed digital asset treasury, @BTCS_SA, has announced a $30M strategic allocation to accumulate $ZIG.
This is a powerful vote of confidence in ZIGChain’s vision for democratizing wealth generation through Real World Asset tokenization. https://t.co/DAC5ioXOx3
— ZIGChain (@ZIGChain) September 29, 2025
BTCS eyes ZIG yield
An expansion to the company’s diversified treasury strategy will also see 60% of the funds deployed towards exposure to Bitcoin (BTC) and 10% to Core (CORE). Deployment into BTCS’s active treasury strategy, unlike the passive “buy and hold” playbook popularized by Strategy.
BTCS’ approach aims to deliver operational revenue and yield – even during episodes of flat markets.
“The inclusion of ZIGChain in BTCS’s treasury strategy highlights a broader shift toward productive digital asset treasuries,” said Abdul Rafay Gadit, co-founder of ZIGChain and member of BTCS’s Supervisory Board.
He added:
“Unlike passive holdings, validators and staking rewards create recurring revenue streams while directly strengthening the networks themselves. We see this model as a sustainable path forward for listed companies seeking transparent and resilient exposure to digital assets.”
ZIGChain price last traded above current levels in late August, while its year-to-date highs of $0.13 came on January 18. The ZIG token traded at the all-time peak of $0.22 in April 2021. Notable ecosystem platforms for the layer 1 chain includes Zignaly, a regulated social investment platform and Zamanat, a Shariah-compliant RWA tokenization platform.
2025-09-29 20:122mo ago
2025-09-29 15:432mo ago
Historic transformation for BTC, ETH in Q4: ETF inflows and regulatory harmony point to a new market reality
Historic transformation for BTC, ETH in Q4: ETF inflows and regulatory harmony point to a new market reality Gino Matos · 17 seconds ago · 4 min read
The market movements are not suggesting just another cyclical rally, but a structural shift that may be permanently changing how digital assets integrate with traditional finance.
Sep. 29, 2025 at 8:42 pm UTC
4 min read
Updated: Sep. 29, 2025 at 8:42 pm UTC
Cover art/illustration via CryptoSlate. Image includes combined content which may include AI-generated content.
The fourth quarter of 2025 is poised to be a watershed moment for crypto markets, driven by institutional capital flows through Bitcoin ETFs and the most significant regulatory coordination effort in US crypto history.
The market movements are not suggesting just another cyclical rally, but a structural shift that may be permanently changing how digital assets integrate with traditional finance.
The numbers tell a compelling story of institutional appetite returning with force after Bitcoin ETFs experienced net outflows through August, resulting in cumulative flows dropping from $54.9 billion to $54.2 billion by month’s end.
September delivered a reversal. Farside Investors’ data highlighted that Bitcoin ETFs attracted $2.56 billion in September alone, bringing the total cumulative flows to nearly $56.8 billion by Sept. 26, completely erasing August’s weakness.
This monthly surge represents more than just recovered momentum, signaling how investors are confident to include Bitcoin in their portfolios.
Capital rotates but Ethereum holds steadyMeanwhile, Ethereum (ETH) ETFs experienced the opposite trajectory after a liquidity rotation to these products.
Farside Investors’ data showed that Ethereum ETF flows increased from $9.65 billion to $13.54 billion in August, driven by Ethereum’s impressive 19% monthly gain and a new all-time high of $4,957.41.
Yet, flows reversed course in September, declining to $13.155 billion as of Sept. 26. This $389 million outflow stresses how capital is rotating back to Bitcoin as the primary institutional crypto play.
Despite the ETF outflow headwinds, Ethereum’s price action reveals structural strength that may be more significant than the headline numbers suggest.
Trading at $4,147.97 as of press time, ETH has demonstrated resilience, particularly during the sharp 6.7% correction on Sept. 25, which briefly pushed the asset below $4,000.
As a result, the swift recovery indicates that demand remains robust even as institutional flows favor Bitcoin this month.
Additionally, Coinglass data indicated that exchange balances for Ethereum reached a one-year low of 13.03 million ETH on Sept. 29, representing a significant decline from 15.48 million ETH at the beginning of August.
This 2.45 million ETH reduction in exchange supply suggests that investors are withdrawing Ethereum for custody rather than selling into weakness, painting an optimistic long-term outlook.
This supply dynamic creates a potential setup for Ethereum’s upward move once institutional attention returns, characterized by a reduced liquid supply and continued demand growth.
Regulatory revolution: the end of US crypto gridlockPerhaps even more transformative than the ETF flows is the unprecedented level of regulatory coordination emerging between the US Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC).
After years of jurisdictional uncertainty and conflicting guidance, both agencies are now pursuing collaborative frameworks that could finally provide the clarity the industry has demanded.
A pivotal moment arrived on Sept. 17 when the SEC approved generic listing standards for commodity-based trust shares across Nasdaq, Cboe, and the New York Stock Exchange. This streamlined approval process marks a dramatic shift from the lengthy reviews that previously plagued crypto ETF applications.
By reducing regulatory delays, the SEC has effectively opened new pathways for broader crypto investment products, with several altcoin ETF applications awaiting final decisions in October.
The regulatory momentum began earlier in February when CFTC Acting Chairman Caroline Pham launched a pilot program exploring the use of tokenized collateral, including stablecoins, in regulated derivatives markets.
By March, both agencies had restarted staff-level conversations, with SEC Commissioner Hester Peirce confirming renewed cooperation efforts. This early coordination set the stage for more ambitious initiatives.
July marked a turning point with SEC Chairman Paul Atkins announcing “Project Crypto,” a commission-wide initiative designed to modernize securities rules for blockchain activity and help shift US markets “on-chain.”
The project aimed to establish clear token classification guidance, create purpose-built exemptions for ICOs and airdrops, and enable SEC-regulated venues to offer comprehensive crypto services under unified licensing.
The regulatory momentum accelerated through September with a series of coordinated announcements. On Sept. 2, both agencies issued a joint staff statement affirming that registered exchanges can offer spot crypto asset products, signaling that regulatory barriers are being systematically removed.
This was followed by Sept. 23 announcements of the CFTC’s tokenized collateral initiative and Atkins’ commitment to implement an “innovation exemption” by year-end.
The Sept. 29 joint roundtable represents the culmination of these efforts, focusing on extended trading hours, portfolio margining frameworks, and DeFi safe harbors.
This level of inter-agency coordination is unprecedented in crypto regulation, signaling a fundamental shift from obstruction to facilitation.
The death of crypto’s 4-year cycleTraditional crypto market analysis has long relied on Bitcoin’s four-year halving cycle to predict major price movements, but institutional participation is fundamentally altering these dynamics.
Bitwise CIO Matthew Hougan argued in July that the cycle’s influence is waning as supply shocks from halvings lose their potency in an increasingly mature market.
The macro environment has also shifted dramatically. Interest rates no longer create the same downward pressure on crypto assets, while clearer regulatory frameworks are reducing the extreme volatility and collapse risks that once defined crypto bear markets.
Instead of boom-bust cycles driven by retail speculation and regulatory crackdowns, the market is witnessing more sustained institutional accumulation.
This structural change is evident in current market behavior, where corporate treasury accumulation and institutional portfolio construction replace whales selling into retail euphoria.
New era of crypto-traditional finance integrationWhat makes the fourth quarter potentially transformative isn’t just the individual developments in ETFs or regulation, but how these forces are converging to blur the lines between crypto and traditional finance.
ETF flows are now amplifying the impact of Federal Reserve policy decisions on crypto markets, while regulatory harmonization is enabling institutional products that were previously impossible.
The extended bull structure in play differs fundamentally from previous cycles. Rather than retail-driven speculation followed by inevitable crashes, institutional participation is fostering more consistent and long-term growth patterns.
This is highlighted by Bitcoin’s fall to historical lows in realized volatility, according to a report by Bybit on Sept. 24.
The regulatory clarity emerging from the coordination between the SEC and CFTC is equally significant. For the first time, US institutions have a clear pathway to offer comprehensive crypto services without navigating conflicting regulatory interpretations.
Amid growing market maturity, the fourth quarter represents a fundamental inflection point. The combination of institutional flows, unprecedented regulatory coordination, and structural market changes suggests Bitcoin and Ethereum are turning from a speculative asset class to an integrated component of the global financial system.
Whether this proves to be crypto’s most transformative moment may depend on how effectively the industry capitalizes on this unprecedented regulatory and institutional momentum.
Mentioned in this articleLatest US StoriesLatest Bitcoin Stories
2025-09-29 20:122mo ago
2025-09-29 15:432mo ago
Ethereum's Rally to $8,000 Incoming, Analyst Says Bearish Noise Will Only Fuel the Surge
Ethereum's Q4 outlook remains bullish after the first meaningful correction since April lows.
Ethereum briefly fell below $3,840 last week as part of a broad slump across the crypto sector. The asset has since bounced back and is trading near $4,110 after rising by 2.43% over the past day.
Experts say shorting Ethereum now is reckless.
“Only Fools Short” ETH
In his latest post on X, analyst Mr. Wall Street said that Ethereum is currently in an extremely bullish setup, and added that recent bearish noise could, in fact, help in fueling a major rally.
According to his analysis, ETH is set to target $7,000-$8,000 in Q4. He explained that this pullback is the first meaningful correction since the $1,500 lows in April, with a healthy 20% decline serving as a necessary reset before further upside. Mr. Wall Street also pointed out that tens of billions in liquidations occurred above previous bull market all-time highs, and believes that shorting Ethereum in this environment would be a mistake.
Meanwhile, crypto analyst Degen Hardy said that bears are on precarious ground if ETH surges to $4,200. According to his analysis, more than $40 billion in liquidations sit just above current levels, which is primed to be triggered in a sharp rally. Hardy highlighted the market’s tension and questioned whether the cryptocurrency will first test lower support levels or surge straight through resistance. The implication is clear: shorts face significant risk, and any decisive upward move could spark cascading liquidations. Such a pattern sets the stage for potentially explosive momentum.
According to Lookonchain data, whale activity in Ethereum remained strong despite recent market volatility. Last week, 16 wallets collectively received 431,018 ETH, which is approximately worth $1.73 billion, from major platforms including Kraken, Galaxy Digital, BitGo, FalconX, and OKX.
More recently, a fresh wallet moved 3,884 ETH, valued at around $15.57 million, from OKX. Another whale wallet, which sold 1,857 ETH ($4.18 million) five months ago at $2,251, repurchased 1,501 ETH ($6.17 million) on Monday at $4,114, which indicated a willingness to buy even at higher price levels.
You may also like:
ETH ‘Historic’ RSI Signal: Analysts Debate Ethereum’s Price Future
Ethereum Accumulator Addresses See Massive 400,000 ETH Inflow in a Single Day
$1 Billion Liquidation Storm Hits as BTC, ETH, XRP Collapse
Ethereum’s No-Sell Wallets Swell
As reported by CryptoPotato earlier, Ethereum accumulator addresses saw a historic inflow of nearly 400,000 ETH on September 24th, following a record 1.2 million ETH accumulation less than a week earlier, according to CryptoQuant. These no-sell wallets have made multiple purchases without any withdrawals.
Such moves, hence, point to strong long-term holder activity, potentially from institutional players or ETH ETF-linked entities. The inflows occurred amid a steep market sell-off driven by macroeconomic concerns.
Tags:
2025-09-29 20:122mo ago
2025-09-29 15:502mo ago
Yearn Finance votes on new proposal to allocate future revenue to stYFI holders
Yearn Finance, a leading DeFi yield aggregator protocol, is in the early stages of a major governance overhaul proposal, YIP-XX. The proposal was introduced by pseudonymous contributor 0xPickles on September 28, 2025, in a bid to align stakeholders and encourage growth.
YFI does not enjoy the same clout it used back in its heyday when it was one of the biggest DeFi protocols with an all-time high of just under $7 billion in deposits as of December 2021.
However, this three-part initiative is expected to help the protocol find its way back to that greatness. It is touted not just as a way to make profitability a priority but also to promote accountability, and directly reward token holders who have stayed through declining participation and a TVL that’s down more than 90% from its all-time high.
Yearn Finance votes on a new proposal
Among the proposed changes, the most notable change is that a majority of all the revenue the protocol generates could soon go directly to those with skin in the game, as they have kept their YFI tokens locked despite the dwindling performance.
“This proposal creates a new deal,” 0xPickles wrote. “90% of future revenue goes to stYFI holders, empowering them.”
That is not a huge amount of money right now, considering Yearn’s monthly revenue from August turned in under $200,000 in profit, per DefiLlama data.
Still, the focus on profitability and increasing accountability is expected to put the protocol on a sustainable growth path that will, over time, increase revenues and make the YFI token more valuable.
The proposal comes as DeFi is enjoying a wave of new liquidity, which has pushed deposits to record heights this year.
For Yearn, which was once one of the biggest DeFi protocols with an all-time high of just under $7 billion in deposits in December 2021, the liquidity provides an opportunity to reclaim the success of the past.
Of course, this is assuming things unfold in the best-case scenario, but that is not certain because it is not the first time Yearn has attempted an overhaul in recent years.
In October 2023, a new vote introduced an escrow token model, like those used by protocols such as Curve Finance, Balancer, and Velodrome, however, even though there was support from YFI token holders, the new model wasn’t widely adopted.
“Only 3.8% of the YFI supply is locked, a figure that is in decline,” 0xPickles pointed out. “This demonstrates a fundamental lack of interest in the model.”
The new simpler model suggested by 0xPickles
0xPickles’ proposal will scrap the vote escrow model in favour of a simpler staking model.
Under the new model, YFI holders will be able to lock up their tokens via staking, which would qualify them to receive a portion of the protocol’s revenue.
Another proposal suggests restructuring the DAO to make it more profit-oriented while mandating on-chain financial reporting to justify budget requests from contributors.
As for what is prompting these changes, the proposal’s author cited organizational misalignment and coordination inefficiency as two cogent reasons.
There is also a final proposal to formalize a plan to distribute 1,700 YFI tokens through strategic contributor incentives, establish a capped performance bonus program, and create a long-term contributor retention pool.
The three proposals are currently being discussed on the Yearn governance forum ahead of a vote. It is being touted as an “all-or-nothing” package because the proposals form a single initiative, which means that for it to take effect, it has to pass in full via a DAO vote.
If you're reading this, you’re already ahead. Stay there with our newsletter.
2025-09-29 20:122mo ago
2025-09-29 15:542mo ago
Could Uptober Fuel Dogecoin Toward $0.35? Analysts Weigh In
Dogecoin (DOGE) has once again attracted investor attention as market momentum builds ahead of potential breakout moves. The cryptocurrency’s history of sharp price spikes, combined with current technical setups, suggests renewed bullish interest. Analysts highlight that key support zones and repeating chart patterns could set the stage for the next leg upward, reinforcing Dogecoin’s reputation as a highly retail-driven asset.
Revisiting Historic BreakoutsAccording to analyst Ali Martinez, Dogecoin’s late January 2021 price surge remains a defining moment. Within a single day, $DOGE jumped 423%, climbing from roughly $0.01 to above $0.05. Following this parabolic move, prices consolidated between $0.07 and $0.08, eventually testing $0.085.
Martinez notes that the 2021 spike established durable support zones near $0.065–$0.07. Consequently, closing above these levels today signals strong market demand, giving traders confidence in potential upward moves. These historic levels continue to guide technical decisions and shape market psychology.
Patterns Pointing to a New PumpTrader Tardigrade highlights that Dogecoin may be primed for another surge, especially against Bitcoin. On the $DOGE/$BTC 4-hour chart, a falling wedge breakout pattern has emerged. Previous breakouts pushed prices from 0.00000200 BTC to above 0.00000285 BTC. A similar formation is now targeting 0.00000270 BTC or higher.
Source: X
The symmetry between past and current setups strengthens the case for a bullish extension. Hence, traders anticipate renewed momentum and a possible repeat of earlier gains.
Uptober Could Strengthen Dogecoin RallyOn the daily chart, Tardigrade identifies a rounding bottom pattern forming near $0.23–$0.24 support. Historically, two strong rallies followed by corrections showed similar behavior, with drops around 28–35%. If Dogecoin holds above $0.23 and surpasses resistance near $0.27, the path toward $0.30 and $0.35 becomes plausible.
Source: X
Additionally, growing market sentiment during October, often called “Uptober,” could reinforce buying pressure. With Dogecoin as of press time priced at $0.2327 and a market cap exceeding $35 billion, the stage is set for potential gains.
ETF Decisions Could Influence Market SentimentNate Geraci, president of NovaDius Wealth Management, emphasizes that upcoming spot crypto ETF rulings could impact multiple altcoins. Solana, XRP, Cardano, Hedera, and Dogecoin all await regulatory clarity. Approval or positive guidance could ignite inflows and reinforce bullish trends across these digital assets.
2025-09-29 20:122mo ago
2025-09-29 16:002mo ago
Altcoin 24H Futures Volume Surpasses BTC and ETH: Warning Sign Or Market Shift?
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure
The altcoin market is navigating a period of volatility and uncertainty, with traders closely watching Bitcoin and Ethereum as they attempt to reclaim key levels. For many investors, the long-awaited altseason—a period where alternative cryptocurrencies outperform BTC—remains more of a hopeful narrative than a present reality. With BTC and ETH dominating market sentiment, smaller assets are caught in a tug-of-war between fading confidence and renewed optimism.
Despite the uncertainty, key data points suggest altcoins are heating up beneath the surface. Futures volumes have started to climb again, and liquidity is showing signs of shifting away from major coins into higher-risk plays. Historically, this kind of behavior often precedes strong rotations within the crypto market, where capital flows into mid- and low-cap tokens once confidence in BTC and ETH stabilizes.
For now, investors remain cautious, with many awaiting confirmation that bullish momentum will return before committing more aggressively. The coming weeks will be critical: if Bitcoin and Ethereum manage to hold above support and reestablish an upward trend, altcoins could be positioned for explosive growth. Until then, volatility will likely define trading conditions, leaving investors balancing both risk and opportunity.
Altcoin Futures Volume Signaling A Move
The altcoin market is drawing increased attention after 24H futures trading volume surpassed that of Bitcoin and Ethereum, according to the latest market data. This shift highlights a surge in speculative activity, with investors pouring liquidity into higher-risk assets. Analyst Ted Pillows explains that despite last week’s sharp flush-out, which cleared overleveraged positions across multiple altcoins, retail traders have quickly returned to the market, embracing what he calls a “full degen mode” approach.
Altcoin 24H volume surpasses BTC and ETH | Source: Ted Pillows
This dynamic raises both opportunities and risks. Elevated trading activity in altcoin derivatives reflects renewed appetite for risk-taking, signaling that investor sentiment has not been entirely derailed by recent volatility.
On the other hand, history shows that when altcoin futures volumes climb disproportionately compared to BTC and ETH, the market often faces heightened liquidation risk. Leveraged bets amplify price swings, and even small corrections can cascade into massive liquidations, dragging prices lower across the board.
Whether it materializes as a breakout to new highs or another round of forced liquidations depends largely on Bitcoin’s ability to stabilize and broader macroeconomic conditions. For now, the message is clear: retail enthusiasm has returned, volumes are rising, and altcoins are once again the focal point of speculative trading. While this sets the stage for explosive price action, it also reinforces the need for caution as the risk of another major liquidation event looms.
Altcoin Market Consolidates
The chart of the total crypto market cap excluding the top 10 coins shows that altcoins continue to trade in a decisive zone around $303B. After several months of consolidation, the market cap has formed a base above the $250B region, a level that acted as resistance in 2023 and now serves as support. This structural shift suggests that altcoins are maintaining strength despite recent volatility in Bitcoin and Ethereum.
Crypto Total Market Cap excluding Top 10 | Source: OTHERS chart on TradingView
The moving averages highlight the trend more clearly: the 50-week SMA remains above the 200-week SMA, keeping a long-term bullish bias intact. However, the market has struggled to reclaim the $400B mark, a key resistance area tested multiple times since early 2024. Each rejection at this level has led to sharp retracements, signaling the importance of $400B as a breakout threshold for the next altseason.
Current price action shows tightening around the 50- and 100-week SMAs, reflecting indecision but also the potential for a strong move once momentum returns. A sustained close above $320B could signal renewed bullish momentum, while a breakdown below $280B may confirm deeper corrections.
Featured image from Dall-E, chart from TradingView
Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.
Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.
Sebastian's journey into the world of crypto began four years ago, driven by a fascination with the potential of blockchain technology to revolutionize financial systems. His initial exploration focused on understanding the intricacies of various crypto projects, particularly those focused on building innovative financial solutions. Through countless hours of research and learning, Sebastian developed a deep understanding of the underlying technologies, market dynamics, and potential applications of cryptocurrencies.
As his knowledge grew, Sebastian felt compelled to share his insights with others. He began actively contributing to online discussions on platforms like X and LinkedIn, focusing on fintech and crypto-related content. His goal was to expose valuable trends and insights to a wider audience, fostering a deeper understanding of the rapidly evolving crypto landscape. Sebastian's contributions quickly gained recognition, and he became a trusted voice in the online crypto community.
To further enhance his expertise, Sebastian pursued a UC Berkeley Fintech: Frameworks, Applications, and Strategies certification. This rigorous program equipped him with valuable skills and knowledge regarding Financial Technology, bridging the gap between traditional finance (TradFi) and decentralized finance (DeFi). The certification deepened his understanding of the broader financial landscape and its intersection with blockchain technology.
Sebastian's passion for finance and writing is evident in his work. He enjoys delving into financial research, analyzing market trends, and exploring the latest developments in the crypto space. In his spare time, Sebastian can often be found immersed in charts, studying 10-K forms, or engaging in thought-provoking discussions about the future of finance.
Sebastian's journey as a crypto analyst and investor has been marked by a relentless pursuit of knowledge and a dedication to sharing his insights. His ability to navigate the complex world of crypto, combined with his passion for financial research and communication, makes him a valuable asset to the industry. As the crypto landscape continues to evolve, Sebastian remains at the forefront, providing valuable insights and contributing to the growth of this revolutionary technology.
2025-09-29 20:122mo ago
2025-09-29 16:002mo ago
Bitcoin ‘wholecoiners' stop selling – What's going on with BTC?
Bitcoin ‘wholecoiners’ stop selling – What’s going on with BTC?
Posted: September 30, 2025
Samyukhtha L KM is a Financial Journalist and Market Analyst at AMBCrypto whose work is defined by one central question: Is the latest trend in blockchain hype, or history in the making?
Her expertise is built on a strong academic foundation, with a Master’s in Journalism and Mass Communication from Amity University and a Bachelor’s in Commerce from the University of Madras. This dual qualification equips her with a unique skill set: the financial acumen to dissect market mechanics and the journalistic rigor to investigate and communicate complex subjects with clarity.
Samyukhtha specializes in analyzing the socio-economic impact of blockchain adoption and assessing the viability of new market narratives. This includes a focus on high-velocity, community-driven assets such as memecoins, where she evaluates sentiment and fundamentals. She is dedicated to providing readers with insightful, well-researched commentary that looks beyond immediate market moves to understand the long-term implications of decentralized technology.
2025-09-29 20:122mo ago
2025-09-29 16:002mo ago
Solana At A Crossroads: This Key Indicator Holds The Key To $175 Or $220
Solana is once again at a pivotal crossroads, with its price hovering around the 50-day EMA —a level that could dictate its next major move. A decisive break above $220 could ignite fresh bullish momentum, while failure to hold could open the door for a slide back toward $175.
SOL Tests 50-Day EMA As Market Watches Closely
Lark Davis, a widely followed crypto analyst on X, recently noted that Solana has returned to test its 50-day EMA. This moving average has historically provided both support and resistance for SOL, making the latest retest a key moment for traders watching the coin’s short-term direction.
In addition, Davis highlighted signs of improving momentum on the indicators. The MACD histograms are curving upward, hinting at a potential shift in momentum from bearish to bullish, while the RSI is slowly rising, suggesting that buying pressure may be building. These developments signal that Solana is preparing for a recovery phase if buyers step in with stronger conviction.
Source: Chart from Lark Davis on X
Despite these encouraging signals, Davis noted that trading volumes remain muted. Low volume often raises concerns about the strength behind a move, as rallies without significant participation can fade quickly.
What To Watch For As Solana Builds Strength
Analyzing the potential outlook for Solana, Lark Davis highlighted two distinct, high-stakes scenarios based on how the asset interacts with the 50-day Exponential Moving Average (EMA). This EMA acts as a pivotal line, and the price’s reaction here will determine the direction of the short-term trend.
The first potential outcome is that if the price is decisively rejected at the 50-day EMA, known as a bearish retest, it would signal weakness and likely lead to a move downward. In this case, the analyst targets the $175 support level as the expected floor. While he qualifies shorting as “nasty business,” he suggests it could be done in this specific situation.
The second outcome, which is a bullish scenario, requires a strong display of conviction from buyers. This involves a successful and robust reclaim of the 50-day EMA, specifically confirmed by today’s daily candle closing above $210. To further solidify this bullish case, the price ideally needs to push beyond the subsequent resistance at the 20-day EMA, which sits near $220.
Given the immediate threat and the potential for a swift upside move, the analyst suggests a high-risk, high-reward play. Initiating a long position from the current price, near $209, with a tight stop-loss might be a sensible strategy to catch the bullish scenario and capitalize on the quick momentum if the price successfully reclaims the 50-day EMA.
SOL trading at $208 on the 1D chart | Source: SOLUSDT on Tradingview.com
Featured image from iStock, chart from Tradingview.com
2025-09-29 19:122mo ago
2025-09-29 14:132mo ago
Chainlink's AI-powered communications tool shows promise at streamlining corporate actions, data sharing globally
The U.S. Securities and Exchange Commission (SEC) has requested that issuers of exchange-traded funds related to XRP, Litecoin (LTC), Solana (SOL), Cardano (ADA), and Dogecoin (DOGE) withdraw pending 19b-4 filings.
Journalist Eleanor Terrett reported the change, stating that the recent approval of generic listing standards by the regulator eliminates the need for individual filings, thereby clearing the path to approval.
🚨SCOOP: The @SECGov has asked issuers of $LTC, $XRP, $SOL, $ADA, and $DOGE ETFs to withdraw their 19b-4 filings following the approval of the generic listing standards, which replace the need for those filings. Am told withdrawals could start happening as soon as this week.
— Eleanor Terrett (@EleanorTerrett) September 29, 2025
These standards are a replacement for the old case-by-case review under Section 19(b) of the Securities Exchange Act. Instead of waiting up to 240 days for a decision, issuers can now rely on predetermined requirements. Exchanges that meet these criteria can proceed directly to the listing process, significantly reducing the overall process. Terrett stressed that this development is a sign that the new framework is working as it is supposed to.
Faster approvals and simplified procedures
Under the new rules, commodity-based ETFs, including those that are linked to cryptocurrencies, can be listed provided they meet eligibility criteria such as having futures contracts under the jurisdiction of the Commodity Futures Trading Commission (CFTC). With this model, the SEC effectively minimizes delays associated with filing reviews and with withdrawal notices.
The final SEC deadlines for some crypto ETF decisions under the 19b-4 process start this month, including for XRP, SOL, and Dogecoin. Crypto issuers such as Fidelity and Franklin Templeton are now modifying their applications accordingly. Additionally, the Issuers are expected to start taking their older submissions back within days.
According to market analysts, the generic listing framework will spur a wave of new spot cryptocurrency ETFs. Unlike earlier filings, which required scrutiny by an individual, the new process brings efficiency while ensuring compliance protection.
Political risks cloud the timeline
Even with the streamlined system, there is uncertainty. Bloomberg analyst James Seyffart cited the impending government shutdown in the US as a possible roadblock. This rule’s effective date falls within the window of time during which the SEC may begin accepting applications for the rule’s waivers, raising questions about staffing and decision-making capacity.
Seyffart’s colleague Eric Balchunas added that it’s not clear yet when these ETFs will launch. With prospectuses being filed months ahead of time, the timing of approval now hinges on the Division of Corporation Finance of the SEC, not statutory deadlines.
To add to further uncertainty in the near term, Polymarket’s prediction market signals a 69% likelihood of a shutdown by October 1. The budget negotiations have already held up the discussion of the CLARITY Act, another crypto-related bill.
Get up to $30,050 in trading rewards when you join Bybit today
2025-09-29 19:122mo ago
2025-09-29 14:212mo ago
SEC's Latest Withdrawal Update Shows ETF Green Light is a Matter of Time as XRP's Lift-Off Looms